Time Interval	VN-NP Telemedicine Algorithm (mean and standard deviation, minutes)

Onset to Door	32.3 ± 20.5

Onset to Call	42.8 ± 21.2

Onset to Lab	110.5 ± 12.0

Onset to Decision	112.6 ± 31.1

Onset to rt-PA	159.0 ± 8.5

Door to Call	19.6 ± 18.7

Door to Consent	39.8 ± 26.0

Door to Lab	75.0 ± 32.4

Door to Neuro Exam	54.2 ± 15.1

Door to CT Reading	78.2 ± 23.4

Door to Decision	69.6 ± 9.6

Call to Consent	21.0 ± 10.8

Call to Neuro Exam	31.5 ± 11.5

Call to Decision	53.2 ± 9.0

Consent to Neuro Exam	9.0 ± 16.8

Consent to Decision	30.7 ± 19.3

Consent to rt-PA	67.0 ± 30.5

Decision to rt-PA	45.5 ± 21.9

Time Interval

Onset to Door

Onset to Call

Onset to Lab

Onset to Decision

Onset to rt-PA

Door to Call

Door to Consent

Door to Lab

Door to Neuro Exam

Door to CT Reading

Door to Decision

Call to Consent

Call to Neuro Exam

Call to Decision

Consent to Neuro Exam

Consent to Decision

Consent to rt-PA

Decision to rt-PA


				SED	Significance

	Year 1	Year 2	Year 3	Treatment	Year	Treatment	Year	Interaction

Livera

 Treated

No.b	11/15	4/14	2/12

Concentration	7.45 (56)	4.36 (19)	— (45)	1.67	1.58	NS	*	NS

 Control

No.	13/14	7/19	2/16

Concentration	10.57 (112)	7.30 (53)	— (265)

Kidney fat

 Treated

No.	1/15	0/14	2/12

Concentration	— (45)	— (ND)	— (134)

 Control

No.	6/15	3/18	3/16

Concentration	— (77)	— (96)	— (29)

Musclea

 Treated

No.	0/15	10/13	9/12

Concentration	— (ND)	14.83 (220)	31.76 (1,009)	3.78	3.78	*	NS	#

 Control

No.	0/15	19/19	11/15

Concentration	— (ND)	42.8 (1,832)	26.3 (692)


Parasite forms	IC50 (μM)	Time (h)	SI

Epimastigotes (Y strain)	255.15 ± 32.6	24	>15

Metacyclic trypomastigotes (Dm28c)	191.8 ± 10.5	24	>21

Bloodstream trypomastigotes (Y strain)	259.4 ± 6.1	24	>16

Intracellular amastigotes (Y strain)	188.2 ± 47.5	48	>21


Algorithm for feature selection	Average sensitivity for 5-fold cross validation (%)	Average specificity for 5-fold cross validation (%)

FDAFSA	84	86

RTPFSGA	94	59

PromoBot[FDAFSA + RTPFSGA]	89	86


Factors	Criteria	Comment

Sea level height in tsunami, tide level in storm surge, flood level	>2.5 m	Unsuitable

2.5–1.5 m	Neutral

<1.5 m	Suitable

Geological environment	Geologically inappropriate areas and near-fault region	Unsuitable

Others	Suitable

Distance from gas stations, natural gas fueling stations, high voltage lines, and power plants	<50 m	Unsuitable

50–100 m	Neutral

>100 m	Suitable

Distance from dangerous goods warehouse	<500 m	Unsuitable

500–1000 m	Neutral

>1000 m	Suitable

Distance from high pressure gas pipelines	<25 m	Unsuitable

25–50 m	Neutral

>50 m	Suitable

Terrain slope	>30°	Unsuitable

15–30°	Neutral

>15°	Suitable

Distance from waters	0–30 m	Neutral

>30 m	Suitable

Terrain elevation	<1.5 m	Neutral

>1.5 m	Suitable

Distance from heritage conservation areas	0–30 m	Neutral

>30 m	Suitable

Distance from waste treatment stations	<100 m	Neutral

>100 m	Suitable


Clinical trial	Median age	Range	≥75 years	PS 2	Visceral metastases

TROPIC	68	62–73	18%	7%	25%

COU-AA-301	69	42–95	28%	10%	11% (liver metastases)

AFFIRM	69	41–92	25%	8.5%	23.2%

Clinical trial	Median age	Range	≥75 years	PS 2	Visceral metastases

AFFIRM	69	41–92	25%	8.5%	23.2%


	n: 78	%

Working status at the time of admission	Yes	68	87.2

No	10	12.8

Sector of work	Industry	17	21.8

Service	61	78.2

Total duration of work (month) Mean ±SD (min - max)	34.6±51 (1-156)

Working status at the time of admission	Yes

No

Sector of work	Industry

Service

Total duration of work (month) Mean ±SD (min - max)


Season	Response	Predictor variables	θ	SE	P-value

Dry	Frequency of occurrence	Distance to permanent water	-2.49E-04	1.11E-04	<0.05

		(Distance to permanent water)2	4.67E-08	2.18E-08	<0.05

		Distance to rangerpost/lodge	1.66E-05	9.30E-06	<0.1

		Wooded grassland	2.31E-01	1.18E-01	<0.1

Dry	Average biomass	Distance to rangerpost/lodge	-7.91E-05	1.79E-05	<0.0001

Wet	Frequency of occurrence	Distance to water	5.04E-04	2.02E-04	<0.05

		(Distance to water)2	-3.42E-07	1.10E-07	<0.01

		Distance to rangerpost/lodge	-5.44E-05	7.88E-06	<0.0001

		Wooded grassland	-1.60E-01	9.81E-02	<0.2

		Dense woodland	-4.61E-01	2.05E-01	<0.05

Wet	Average biomass	Distance to rangerpost/lodge	-5.18E-05	1.77E-05	<0.01

		Open grassland	1.37E + 00	2.16E-01	<0.0001

		Open woodland	1.60E + 00	4.23E-01	<0.001


Type of samples collected	Personal breathing zone mass concentrations (μg/m3)	Study

Estimated inhalable mass	0.7 - 53	Maynard et al. 2004 [21]

Total gravimetric mass	N.D. - 331.7	Han et al. 2008 [19]

Total gravimetric mass	7.8 - 320.8	Lee et al. 2010 [20]

Total carbon-inhalable size fraction	64-1094	Methner et al. 2010 [25]

Elemental carbon- inhalable size fraction	N.D. - 38	Methner et al. 2012 [24]

Elemental carbon- inhalable size fraction	N.D. - 7.86	Dahm et al. 2012 [23]

Elemental carbon- respirable size fraction	45 - 80	Birch et al. 2011 [22]


		Culture (MGIT + LJ)

		Positive	Negative	Total

Magnetic bead FM (with blinded re-checking of discrepants)

	Positive	76	12	88

	Negative	31	163	194

	Total	107	175	282

Sensitivity, %(95% CI)	71.0%(61.5 - 79.4)

Specificity, %(95% CI)	93.1%(88.3 - 96.4)

Overall accuracy, %(95% CI)	84.8%(80.0-88.7)

PPV, %(95% CI)	86.4%(77.4-92.8)

NPV, %(95% CI)	84.0%(80.0-88.7)


	Adjusted odds of treatment success (cure/completed) vs. failure/relapse(N = 1,302)OR (95% CI)	Adjusted odds of treatment success (cure/completed) vs. failure/relapse/death(N = 1,483)OR (95% CI)	Adjusted odds of treatment success (cure/completed) vs. failure/relapse/death/lost to follow-up(N = 1,864)OR (95% CI)

HIV

 No	1.7 (0.9; 3.4)	2.7 (1.7; 4.2)	2.3 (1.6; 3.4)

 Yes	Reference	Reference	Reference

Regimen

 Standardized	2.7 (1.8; 3.9)	1.4 (1.1; 1.9)	1.0 (0.8; 1.3)

 Individualized	Reference	Reference	Reference

First DR-TB episode

 Yes	8.8 (5.7; 13.5)	5.4 (3.8; 7.7)	2.1 (1.1; 4.1)

 No	Reference	Reference	Reference

AFB positive

 No	4.2 (2.1; 8.2)	2.1 (1.4; 3.1)	2.1 (1.5; 2.8)

 Yes	Reference	Reference	Reference

Bilateral disease	–

 No		1.4 (1.1.; 1.9)	1.3 (1.1; 1.6)

 Yes		Reference	Reference

Number of previous regimens	–	–	0.4 (0.2; 0.7)

Diabetes	–	–

 No/Unknown			0.7 (0.5; 0.9)

 Yes			Reference

Macro-region			–

 North	0.9 (0.3; 2.2)	0.9 (0.5; 1.5)	–

 Northeastern	0.2 (0.1; 0.5)	0.4 (0.4; 0.7)

 Centre-West	0.4 (0.1; 1.8)	1.0 (0.4; 2.6)

 Southeastern	0.4 (0.2; 0.8)	0.7 (0.5; 1.1)

 South	Reference	Reference


Universe	Registered users of the private area of Company XX’s website who had used this service at least once

Sampling procedure	By means of a structured survey accessed online

Sample	23,223

Scope	Spain

Real sample	4,178

Sampling error	±1.05%

Level of confidence	95% (Z = 1.96)

Maximum variance allowed	P = q = 50%

Fieldwork	June/July 2016

Universe	Registered users of the private area of Company XX’s website who had used this service at least once

Scope	Spain

Real sample	4,178

Sampling error	±1.05%

Level of confidence	95% (Z = 1.96)

Maximum variance allowed	P = q = 50%

Fieldwork	June/July 2016


Parameter	Control	CHD	IS	PCHD	PIS

Number	622	579	546	-	-

Male/female	446/176	431/148	394/152	0.286	0.862


Territory	Northwest Territories (NT)	Nunavut	Nunavik

Region	NT (all)	ISR only	Nunavut (all)	Kitikmeot	Kivalliq	Qikiqtani	Nunavik

Average cost per live birth	$1,412	$690	$12,132	$22,375	$14,608	$8,254	$10,333


GA at delivery	Stillborn	Live born

n	%	n	%

<37 weeks	17	85	27	82

37–42 weeks	3	15	5	15

>42 weeks	0	0	1	3

GA at delivery

<37 weeks

37–42 weeks

>42 weeks


Sensor Response	Body Movement

	Abnormal	Normal

Detection	48	3

No detection	0	45


Characteristic	Percent

Race

 White	15

 African American	85

Maternal smoking at time of pregnancy

 No	44

 Yes	56

Breast-fed

 Yes	6

 No	94

No. of older siblings

 0	25

 1	25

 ≥ 2	50

Maternal height (cm)

 144–155.9	29

 156–165.9	54

 166–181	17

Maternal prepregnancy BMI (kg/m2)

 16–19.9	21

 20–24.9	47

 25–29.9	23

 30–44	9

Maternal age at menarche (years)

 8–11	21

 12	29

 13	25

 ≥ 14	26

Maternal age at enrollment in CPP (years)

 13–19	23

 20–24	36

 25–29	23

 30–42	18

Family SEI at time of pregnancy

 0–2.5	17

 2.6–5.0	59

 ≥ 5.1	24


	Suicidal ideation	Depressive symptoms	Loneliness

	B	SE	β	B	SE	β	B	SE	β

STEP 1

Size of the discrepancy	0.03	0.01	0.35**	0.35	0.13	0.26**	0.09	0.14	0.06

Direction of the discrepancy	0.03	0.01	0.22*	0.65	0.19	0.33**	0.43	0.20	0.21*

STEP 2

Size of the discrepancy*	0.04	0.02	0.53*	0.75	0.27	0.59**	0.79	0.29	0.61**

Direction of the discrepancy


Raman reporter	λmax (nm)	λ0(nm)	Reference

Carboxyfluorescein (FAM)	494	514.5	[85]

Rhodamine 6 G (R6G)	524	514.5, 532	[85–88]

TRITC-DHPE	540	514.5	[89]

Carboxy-X-rhodamine (ROX)	585	514.5, 632.8	[85]

BIODIPY TR-X	588	632.8	[85]

Crystal violet (CV)	590	514.5, 647.1	[86, 90]

Malachite green (MG)	618	632.8	[91]

Malachite green isothiocyanate (MGITC)	625	632.8	[91]

Methylene blue 	570–760∤	785	[92, 93]

Cy5.5	683	632.8	[85]

3,3′-diethylthiatricarbocyanine iodide (DTTC)	765	785	[94]

Raman reporter	λmax (nm)	λ0(nm)

Carboxyfluorescein (FAM)	494	514.5

Rhodamine 6 G (R6G)	524	514.5, 532

TRITC-DHPE	540	514.5

Carboxy-X-rhodamine (ROX)	585	514.5, 632.8

BIODIPY TR-X	588	632.8

Crystal violet (CV)	590	514.5, 647.1

Malachite green (MG)	618	632.8

Malachite green isothiocyanate (MGITC)	625	632.8

Methylene blue	570–760∤	785

Cy5.5	683	632.8

3,3′-diethylthiatricarbocyanine iodide (DTTC)	765	785


Group	Mean increase (106 × cm/s)	SEM	P-value

Control	5.3962	±0.4043	<0.001

Lithium 0.2 mmol/L	2.9419	±0.1747	<0.001


Relationship to patient	N (%)i

Wife/partner	444 (86.4)

Other relative	13 (2.2)

Friend	2 (0.3)

Other	22 (3.7)

Age (years)

< 54	68 (11.4)

55-64	190 (31.9)

65-74	225 (37.8)

75+	96 (16.1)

Overall health

Very good	154 (25.9)

Good	280 (47.1)

Fair	118 (19.8)

Poor	18 (3.0)

Very poor	5 (0.8)

Ethnicity

White British/Irish	562 (94.5)

South Asian	3 (0.5)

African/Caribbean	5 (0.8)

Other	0 (0)

Current situation

Employed	136 (22.9)

Retired	388 (65.2)

Other	35 (5.9)

Current or most recent occupation

Professional	136 (22.9)

Managerial	51 (8.6)

Clerical	164 (27.6)

Technical/craft	7 (1.2)

Manual/service	82 (13.8)

Relationship to patient	N (%)i

Professional	136 (22.9)

Managerial	51 (8.6)

Clerical	164 (27.6)

Technical/craft	7 (1.2)

Manual/service	82 (13.8)


	Methods	Negative effects	Number of published papers (PubMed 1975–2015)

In vivo human studies	Biomonitoring methodsCorrelation studiesCross-sectional studiesPlasma/urine determinations (ELISA, GC/MS,HPLC, LC/MS)	General toxicityReproduction and developmentNeurodevelopment and neuroendocrine systemImmune systemCardiovascular systemMetabolism (diabetes, weight gain, obesity)GenotoxicityCarcinogenicity	442

In vivo animal studies (mice, rats, monkeys)	Prenatal exposureNeonatal exposureAdult animals	Immune systemMetabolism (glucose intolerance, hyper- insulinaemia, diabetes, weight gain, hyper- tryglyceridemia)CancerReproduction and development	565


Characteristic	n	%

Sex

Female	1150	48.4

Male	1078	54.6

Age

≤15	572	26.8

16	593	27.8

17	457	21.4

≥18	514	24.1

Grade

9-10	1299	60.4

11-12	851	39.5

Income per capita (Euros)

Lowest (0–200 TL) (0–97 Euros)	479	30.7

Lowest middle (201–400 TL) (98–193 Euros)	555	35.6

Upper middle (401–600 TL) (194–290 Euros)	216	13.8

Highest (601 TL +) (291 Euros and over)	311	19.9

Social class

Blue collar/Unemployed	956	46.9

Self Employed	444	21.8

Employer	170	8.3

White collar/Manager	468	23.0

Mother’s Education

Illiterate/Only literate	139	6.4

Primary (5 years)	908	41.7

Secondary (8 years)	370	17.0

High school (11 years)	426	19.6

University (13+ years)	332	15.3

School Type

Trade high school	285	13.3

Technical high school for girls	212	9.9

Standard high school	558	26.0

Industrial technical high school	489	22.7

Anatolian/Science/Private high school	606	28.2

Mobile phone utilization

Yes	2005	92.0

No	175	8.0


Document type	Diagnosis	Signs/symptoms	Diagnosis or symptoms

DMH consult notes	11 (44%)	13 (52%)	13 (52%)

Physician notes	1 (.06%)	8 (32%)	8 (32%)

Discharge summary	4 (16%)	11 (44%)	11 (44%)

Nursing Notes	-	14 (56%)	14 (56%)

ICD-9 diagnosis code	7 (28%)	-	7 (28%)

Unique veterans including DMHC notes	14 (56%)	16 (64%)	16 (64%)

Unique veterans excluding DMHC notes	9 (36%)	16 (64%)	16 (64%)

Document type	Diagnosis

DMH consult notes	11 (44%)

Physician notes	1 (.06%)

Discharge summary	4 (16%)

Nursing Notes	-

ICD-9 diagnosis code	7 (28%)

Unique veterans including DMHC notes	14 (56%)

Unique veterans excluding DMHC notes	9 (36%)


	Number	Average bleeding volume (ml)	Average exposure time (min)

Group A	34	8.2 ± 2.3	3.2 ± 2.1

Group B	32	6.8 ± 1.2	2.8 ± 1.7

Group C	36	15.4 ± 1.3	3.6 ± 2.5

	Number	Average bleeding volume (ml)	Average exposure time (min)

G		8.2	3.2 ±


	Odds ratio	P

Oxygen treatment	4,27	<0,01

Systolic BP < 100	3,28	<0,01

Heart rate > 110	2,14	<0,01

Respiratory rate > 22	2,71	<0,01

SpO2 < 94 %	1,67	<0,01


Predictor variables	Regression Type	R2[1]	SSE [2]	Significance F (p<0.05) p value [3]	Model Validation [criterion]	ΔAIC [4]	Preferred model of regression [criterion]

FT4	Linear	0.004	2728.62	0.6533	Reject model [3]	-2.61	Polynomial [1,2,4]

Polynomial	0.09	2501.08	0.1026	Reject model [3]

Pretreatment period	Linear	0.07	2539.30	0.0502	Reject model [3]	-23.88	Polynomial [1,2,4]

Polynomial	0.43	1558.26	<0.0001	Accept model [3]

CO	Linear	0.35	1763.9	<0.0001	Accept model [3]	-9.54	Polynomial [1,2,4]

Polynomial	0.48	1418.57	<0.0001	Accept model [3]

Age	Linear	0.48	1411.17	<0.0001	Accept model [3]	-9.08	Polynomial [1,2,4]

Polynomial	0.58	1144.82	<0.0001	Accept model [3]

Systolic BP/24h	Linear	0.81	497.04	<0.0001	Accept model [3]	-0.09	Polynomial [1,2,4]

Polynomial	0.83	477.79	<0.0001	Accept model [3]

PVR	Linear	0.84	427.39	<0.0001	Accept model [3]	-5.39	Polynomial [1,2,4]

Polynomial	0.86	371.74	<0.0001	Accept model [3]


Protein name	Corresponding gene name	Primers: Forward (F) & Reverse (R)

Caspase 3	CASP3	F: 5’-CGGAAGCAGTGCAGACGCGG-3’

R: 5’-GCTGCGAGCACTCACGAAACTCTTC-3’

Bcl-2	BCL2	F: 5’-TCAACCGGGAGATGTCGCCCC-3’

R: 5’-ACAAAGGCATCCCAGCCTCCGTT-3’

Bax	BAX	F: 5’-AAACTGGTGCTCAAGGCCC-3’

R: 5’-TGAGGAGTCTCACCCAACCA-3’

Cytochrome c	CYCS	F: 5’-ATGGTCTCTTTGGGCGGAAG-3’

R: 5’-CTCCCCAGATGATGCCTTTGT-3’

Collagen I	COL1A1	F: 5’-ACGAAGACATCCCACCAATC-3’

R: 5’-AGATCACGTCATCGCACAAC-3’

Collagen III	COL3A1	F: 5’-GCCTCCCGGAAGTCAAGGAGAAAG-3’

R: 5’-CTTTAGGACCGGGGAAGCCCATG-3’

αSMA	αSMA	F: 5’-CTGCTGAGCGTGAGATTGTC-3’

R: 5’-CTCAAGGGAGGATGAGGATG-3’

GAPDH	GAPDH	F:5’-TCTTTTGCGTCGCCAGCCGAG-3’

R:5’-TGACCAGGCGCCCAATACGAC-3’

Protein name	Corresponding gene name

Caspase 3	CASP3

Bcl-2	BCL2

Bax	BAX

Cytochrome c	CYCS

Collagen I	COL1A1

Collagen III	COL3A1

αSMA	αSMA

GAPDH	GAPDH

Primers: Forward (F) & Reverse (R)

F: 5’-CGGAAGCAGTGCAGACGCGG-3’

R: 5’-GCTGCGAGCACTCACGAAACTCTTC-3’

F: 5’-TCAACCGGGAGATGTCGCCCC-3’

R: 5’-ACAAAGGCATCCCAGCCTCCGTT-3’

F: 5’-AAACTGGTGCTCAAGGCCC-3’

R: 5’-TGAGGAGTCTCACCCAACCA-3’

F: 5’-ATGGTCTCTTTGGGCGGAAG-3’

R: 5’-CTCCCCAGATGATGCCTTTGT-3’

F: 5’-ACGAAGACATCCCACCAATC-3’

R: 5’-AGATCACGTCATCGCACAAC-3’

F: 5’-GCCTCCCGGAAGTCAAGGAGAAAG-3’

R: 5’-CTTTAGGACCGGGGAAGCCCATG-3’

F: 5’-CTGCTGAGCGTGAGATTGTC-3’

R: 5’-CTCAAGGGAGGATGAGGATG-3’

F:5’-TCTTTTGCGTCGCCAGCCGAG-3’

R:5’-TGACCAGGCGCCCAATACGAC-3’


	Side of Surgery

Baseline INVOS	Left surgery	Right surgery S	P

Left baseline INVOS	67.96 ± 7.30	65.91 ± 8.80	NS

Right baseline INVO	66.24 ± 6.85	65.66 ± 8.99	NS

	Side of Surgery

Baseline	Left surg	Righ	P

 INVOS	ery	t surgery S

Left baseline INVOS	67.96 ± 7.30	65.91 ± 8.80	NS

Right baseline INVO	66.24 ± 6.85	65.66 ± 8.99	NS


Ingredients	Content (%)	Nutrients (3)

Corn	64.5	Digestible Energy, MJ/kg	13.81

Whey powder	5.0	Crude Protein (%)	19.82

Soybean meal	23.0	Calcium (%)	0.70

Fish meal	5.0	Total Phosphorus (%)	0.64

L-Lysine HCl	0.2	Lysine (%)	1.22

CaHPO4	0.7	Sulfur Amino Acid (%)	0.65

Pulverized Limestone	0.3	Threonine (%)	0.75

NaCl	0.3	Trptophan (%)	0.22

Premix (2)	1.0

Total	100.0

Ingredients	Content (%)	Nutrients (3)

Pulverized Limestone	0.3	Threonine (%)	0.75

NaCl	0.3	Trptophan (%)	0.22

Premix (2)	1.0

Total	100.0


Source organ	Adult maleMBq-h/MBq	SD	Adult femaleMBq-h/MBq	SD

Brain	3.43E-02	3.18E-03	3.90E-02	1.17E-02

Red marrow	1.37E-03	8.13E-04	1.40E-03	4.67E-04


	DM, g/kg	g/kg, DM basis

Crude protein	Ether extract	Crude ashes	NDF	ADF	Starch

Experimental diets

LP HD	929	229	120	66	83	27	464

HP HD	935	3		82	1	27	364

	DM, g/kg	g/kg, DM basis

Crude protein	Ether extract	Crude ashes	NDF	ADF	Starch

		04	140		09

HP LD	938	303	124	123	111	33	338

Undigested residues

LP HD	-	159	35.7	215	539	175	41.4

HP HD	-	174	47.2	259	481	124	28.7

HP LD	-	212	24.4	339	411	125	9.0


Coping		T1	T2	Within group	Effect size

	Mean	SD	Mean	SD	df	t

Active coping	NET-R	3.40	1.07	5.40	1.35	9	3.87**	1.57

Reframing	NET	4.40	1.90	5.50	2.01	9	2.91*	0.54

	NET-	4	1.64	6.7	1.		2.6	1.


Content (no of questions)

Gen. Pharmacology (3)

Effect (3)

Side effects (3)

Formulations (2)

Interactions (1)

Generics (2)

Pharmacology (14)

Regulations (2)

Storage (4)

Dispensation (4)

Administration (4)

Drug management (14)

Conversion of units (7)

Dose-quantity-strength (4)

Infusions (2)

Dilutions (1)

Drug dose calculations (14)

Totalt (42)


Name	Accession

IAI39	NC_011750.1

SMS-3	NC_01


Atypical antipsychotics	Typical antipsychotics	Alternatives

Clozapine	Haloperidol	Individual therapy

Risperidone	Loxapine	Family therapy

Olanzapine	Molindone	Skill building and psychoeducation


	Clinical presentation and Symptoms

GIST localization	GI bleeding	Abdominal pain	Acute abdomen	Palpable mass	Asymptomatic

Gastric	8	11	-	2	6

Duodenal	2	1	-	-	-

Jejunal	1	1	2	1	2

Small bowel	2	1	3	1	1

Rectal	1	2	-	-	-

Esophageal	-	1	-	-	-

EGIST	-	1	-	1	-

	Clinical presentation and Symptoms

GIST localization	GI bleeding	Abdominal pain	Acute abdomen	Palpable mass	Asymptomatic

Small bowel	2	1	3	1	1

Rectal	1	2	-	-	-

Esophageal	-	1	-	-	-

EGIST	-	1	-	1	-


Code	Value	% age	Description

J	190	9.3	Translation, ribosomal structure and biogenesis

A	0	0.0	RNA processing and modification

K	144	7.1	Transcription

L	102	5.0	Replication, recombination and repair

B	0	0.0	Chromatin structure and dynamics

D	31	1.5	Cell cycle control, cell division, chromosome partitioning

V	52	2.6	Defense mechanisms

T	56	2.8	Signal transduction mechanisms

M	105	5.2	Cell wall/membrane biogenesis

N	14	0.7	Cell motility

U	21	1.0	Intracellular trafficking and secretion

O	57	2.8	Posttranslational modification, protein turnover, chaperones

C	60	2.9	Energy production and conversion

G	177	8.7	Carbohydrate transport and metabolism

E	132	6.5	Amino acid transport and metabolism

F	90	4.4	Nucleotide transport and metabolism

H	79	3.9	Coenzyme transport and metabolism

I	66	3.2	Lipid transport and metabolism

P	79	3.9	Inorganic ion transport and metabolism

Q	25	1.2	Secondary metabolites biosynthesis, transport and catabolism

R	133	6.5	General function prediction only

S	108	5.3	Function unknown

-	434	21.3	Not in COGs

Code	Value	% age	Description

S	108	5.3	Function unknown

-	434	21.3	Not in COGs


Parameters	At start of CRRT	During dialysis period

Creatinine, mg/dl	2.7 ± 1.3

eGFR, CKD-EPI	24.7 ml/minute

Cystatin C, mg/dl	3.2 ± 1.1

GFR, cystatin C	17.7 ml/minute

Bilirubin, mg/dl	9.5 ± 10.6	7.9 ± 6.8

Albumin, g/L	24.7 ± 7.0	25.0 ± 4.1

Cholinesterase, ×1000 IE/L	2.8 ± 1.7	2.6 ± 1.2

ICG-PDR	7.6 ± 5.8	9.9 ± 6.3

MELD score	29.8 ± 5.1

Parameters

Creatinine, mg/dl

eGFR, CKD-EPI

Cystatin C, mg/dl

GFR, cystatin C

Bilirubin, mg/dl

Albumin, g/L

Cholinesterase, ×1000 IE/L

ICG-PDR

MELD score


Questions about physical activity counseling	Possible answers

Relevance

It is important that physical activity programs for the community are offered by the health system.	(a) Strongly disagree (b) Disagree (c) Agree (d) Strongly agree

Viability of offering physical activity programs at primary health care units.	(a) Yes (b) No

Priority in offering physical activity programs in health units.	(a) Yes (b) No

Who is the main health professional responsible for promoting physical activity in the unit?	(a) Physician (b) Nurse (c) Physical education professional (d) Nutritionist (e) Physiotherapist (f) Others

What difficulties do you face with regard to physical activity counseling?	(a) Lack of knowledge (b) Lack of time (c) Lack of places for physical activity practice nearby the unit (d) Others

Physical activity assessment

Do you usually ask about the physical activity level of your patients?	(a) Yes (b) No

If so, what method do you employ?	(a) General questions about engagement in physical activity (b) Specific questions about sedentary time (c) Questions about duration, type and intensity of activities (d) Standardized questionnaires (e) Other method

Knowledge about physical activity guidelines

How do you rate your knowledge about the current recommendations on physical activity for health?	(a) Know enough (b) Would like to learn more (c) Have insufficient knowledge

What is the minimum number of days per week that individuals should perform of physical activity of moderate intensity in order to achieve health benefits?	__ days per week

On these days, what is the minimum time recommended to obtain health benefits?	__ __ __ minutes

How should moderate-intensity physical activity be performed to have a positive impact on health?	(a) One bout per day (b) Can be done in 2–3 bouts per day

What is the minimum number of days per week that individuals should perform of physical activity of vigorous intensity in order to achieve health benefits?	__ days per week

On these days, what is the minimum time recommended to achieve health benefits?	__ __ __ minutes

How should vigorous-intensity physical activity be performed to have a positive impact on health?	(a) One bout per day (b) Can be done in 2–3 bouts per day

People can combine moderate-intensity activities (e.g. walking) with vigorous-intensity activities (e.g. running) for meeting physical activity guidelines?	(a) Strongly disagree (b) Disagree (c) Agree (d) Strongly agree

Questions about physical activity counseling	Possible answers

Physical activity assessment

Do you usually ask about the physical activity level of your patients?	(a) Yes (b) No

If so, what method do you employ?	(a) General questions about engagement in physical activity (b) Specific questions about sedentary time (c) Questions about duration, type and intensity of activities (d) Standardized questionnaires (e) Other method

Knowledge about physical activity guidelines

How do you rate your knowledge about the current recommendations on physical activity for health?	(a) Know enough (b) Would like to learn more (c) Have insufficient knowledge

What is the minimum number of days per week that individuals should perform of physical activity of moderate intensity in order to achieve health benefits?	__ days per week

On these days, what is the minimum time recommended to obtain health benefits?	__ __ __ minutes

How should moderate-intensity physical activity be performed to have a positive impact on health?	(a) One bout per day (b) Can be done in 2–3 bouts per day

What is the minimum number of days per week that individuals should perform of physical activity of vigorous intensity in order to achieve health benefits?	__ days per week

On these days, what is the minimum time recommended to achieve health benefits?	__ __ __ minutes

How should vigorous-intensity physical activity be performed to have a positive impact on health?	(a) One bout per day (b) Can be done in 2–3 bouts per day

People can combine moderate-intensity activities (e.g. walking) with vigorous-intensity activities (e.g. running) for meeting physical activity guidelines?	(a) Strongly disagree (b) Disagree (c) Agree (d) Strongly agree


Enzyme	Extension rate (nt/s)	Processivity (nt)	Kd [DNA] (nM)

Taq (wt)	50	20	102

Taq 42	85	20	2.75

Taq 1C2	ND	ND	1.9

E507K	85	20	1.1

G59W	ND	ND	91.6


	p value	OR	95% CI

Lower	Upper

Gender	0.422	1.171	0.797	1.722


Symbol	Entrez Gene ID	Description

AHRR	57491	Aryl-hydrocarbon receptor repressor

AKR1C3	8644	Aldo-keto reductase family 1, member C3

AXIN2	8313	Axin2

BCL6	604	B-cell CLL/lymphoma 6

BIRC3	330	Baculoviral IAP repeat containing 3

CARD15	64127	Nucleotide-binding oligomerization domain containing 2

CAT	847	Catalase

CCL5	6352	Chemokine (C-C motif) ligand 5

CCNH	902	Cyclin H

FTHFD	10840	Aldehyde dehydrogenase 1 family, member L1

GATA3	2625	GATA binding protein 3

GSTM3	2947	Glutathione S-transferase mu 3 (brain)

HSD17B4	3295	Hydroxysteroid (17-beta) dehydrogenase 4

IGF1R	3480	Insulin-like growth factor 1 receptor

IL1A	3552	Interleukin 1, alpha

INSR	3643	Insulin receptor

MASP1	5648	Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor)

MBD2	8932	Methyl-CpG binding domain protein 2

MMP1	4312	Matrix metallopeptidase 1 (interstitial collagenase)

MYBL2	4605	V-myb myeloblastosis viral oncogene homolog (avian)-like 2

NEDD5	4735	Septin 2

OPRM1	4988	Opioid receptor, mu 1

PARP4	143	Poly (ADP-ribose) polymerase family, member 4

PGR	5241	Progesterone receptor

PIM1	5292	Pim-1 oncogene

RERG	85004	RAS-like, estrogen-regulated, growth inhibitor

TNKS	8658	Tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase

TP53I3	9540	Tumor protein p53 inducible protein 3

XPC	7508	Xeroderma pigmentosum, complementation group C

Symbol	Entrez Gene ID	Description

MBD2	8932	Methyl-CpG binding domain protein 2

MMP1	4312	Matrix metallopeptidase 1 (interstitial collagenase)

MYBL2	4605	V-myb myeloblastosis viral oncogene homolog (avian)-like 2

NEDD5	4735	Septin 2

OPRM1	4988	Opioid receptor, mu 1

PARP4	143	Poly (ADP-ribose) polymerase family, member 4

PGR	5241	Progesterone receptor

PIM1	5292	Pim-1 oncogene

RERG	85004	RAS-like, estrogen-regulated, growth inhibitor

TNKS	8658	Tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase

TP53I3	9540	Tumor protein p53 inducible protein 3

XPC	7508	Xeroderma pigmentosum, complementation group C


Variable	SCI dogs (n = 44)	Healthy control dogs (n = 21)

Dogs

Median age	5.75 years	3 years

MFS at admission	2.5	N/A

TSCIS at admission	6	N/A

Injury to anesthesia time	36.5 h	N/A

Sex characteristics

Female intact	4 (9 %)	0 (0 %)

Female spayed	18 (41 %)	3 (14 %)

Male intact	8 (18 %)	5 (24 %)

Male neutered	14 (32 %)	13 (62 %)

Breeds

Dachshund	34 (76 %)	0 (0 %)

Labrador retriever	0 (0 %)	7 (33 %)

Mixed breed	4 (9 %)	5 (24 %)

Injuries

T12–13	6 (14 %)	N/A

T13–L1	13 (30 %)	N/A

L1–L2	5 (11 %)	N/A

L2–L3	8 (18 %)	N/A

Other thoracic	8 (18 %)	N/A

Other lumbar	4 (9 %)	N/A

Treatments

Non-steroidal anti-inflammatory drugs	17 (39 %)	0 (0 %)

Glucocorticoids	14 (32 %)	0 (0 %)

Both	3 (<1 %)	0 (0 %)

Variable	SCI dogs (n = 44)	Healthy control dogs (n = 21)

Female spayed	18 (41 %)	3 (14 %)

Male intact	8 (18 %)	5 (24 %)

Male neutered	14 (32 %)	13 (62 %)

Breeds

Dachshund	34 (76 %)	0 (0 %)

Labrador retriever	0 (0 %)	7 (33 %)

Mixed breed	4 (9 %)	5 (24 %)

Injuries

T12–13	6 (14 %)	N/A

T13–L1	13 (30 %)	N/A

L1–L2	5 (11 %)	N/A

L2–L3	8 (18 %)	N/A

Other thoracic	8 (18 %)	N/A

Other lumbar	4 (9 %)	N/A

Treatments

Non-steroidal anti-inflammatory drugs	17 (39 %)	0 (0 %)

Glucocorticoids	14 (32 %)	0 (0 %)

Both	3 (<1 %)	0 (0 %)


Variable	Value

Body length (from snout to vent) (cm)	45.07 ± 2.83

Length of tail (cm)	6.07 ± 0.85

Length of left vas deferens from testis to vent (cm)	15.30 ± 1.21

Length of right vas deferens from testis to vent (cm)	11.74 ± 1.003

Weight of right testis (mg)	123.07 ± 16.01

Weight of left testis (mg)	93.07 ± 17.02

Volume of right testis (mL)	0.12 ± 0.03

Volume of left testis (mL)	0.06 ± 0.01

Length of right testis (mm)	21.77 ± 3.70

Length of left testis (mm)	16.69 ± 3.95


	Ever diagnosed with asthmaa(N = 5,646)	Wheeze in past 12 monthsb(N = 5,647)	Ever diagnosed with bronchitisc(N = 7,114)

	No. cases	OR (95% CI)	No. cases	OR (95% CI)	No. cases	OR (95% CI)

Gas stove used with ventilation

No	263	1 Ref.	555	1 Ref.	184	1 Ref.

Yes	224	0.68 (0.45, 1.04)	458	0.62 (0.44, 0.89)*	128	0.61 (0.38, 0.98)*

Gas stove used for heating

Yes	382	1 Ref.	795	1 Ref.	239	1 Ref.


Extract	Total saponina	Rg1 	Re 	Rd

Content (%)	Content (%)	Content (%)	Content (%)

GTS	66.9 ± 1.5	4.9 ± 0.2	3.4 ± 0.1	1.6 ± 0.1

Extract	Content (%)	Content (%)	Content (%)	Content (%)

GTS	66.9 ± 1.5	4.9 ± 0.2	3.4 ± 0.1	1.6 ± 0.1


Partition	Resolution1

rRNA MAFFT	95%

rRNA BAli-Phy	95%

CAD	91%

EFF1	79%

EFF2	67%

POL	77%

CO1	74%

Morphology	91%


Variable	Carotid Score	m-IMT	Left Ventricular Mass

Age	r = 0.53p < 0.01	r = 0.46p < 0.01	-

Weight	-	-	r = 0.53p < 0.01

Height	-	-	r = 0.38p < 0.05

Body Mass Index	-	-	-

Waist Circumference	-	-	r = 0.57p < 0.001

Systolic BP	-	-	-

Diastolic BP	-	-	-

Pulse Pressure	-	-	-

Heart Rate	-	-	-

Total Cholesterol	-	-	-

HDL Cholesterol	-	-	-

Total/HDL Ratio	-	-	-

Triglycerides	-	-	-

Glucose	-	-	-

Insulin	-	-	-

Creatinine	-	-	-

Uric acid	-	-	-

Progetto CuoreScore	r = 0.55p < 0.001	r = 0.36p < 0.05	-

Progetto CuoreScore – Logarithm	r = 0.54p < 0.01	r = 0.43p < 0.05	-

Variable	Carotid Score	m-IMT	Left Ventricular Mass

Pulse Pressure	-	-	-

Heart Rate	-	-	-

Total Cholesterol	-	-	-

HDL Cholesterol	-	-	-

Total/HDL Ratio	-	-	-

Triglycerides	-	-	-

Glucose	-	-	-

Insulin	-	-	-

Creatinine	-	-	-

Uric acid	-	-	-

Progetto CuoreScore	r = 0.55p < 0.001	r = 0.36p < 0.05	-

Progetto CuoreScore – Logarithm	r = 0.54p < 0.01	r = 0.43p < 0.05	-


	MCF-7

SSTR1	++

SSTR2	+++

SSTR3	+

SSTR4	++++

SSTR5	+


Characteristic	Coefficient (95% CI)	p-value

Treatment regimen		0.04

 Prophylaxis	10.0 (0.7, 19.3)

 On-demand	reference

Chronic painb		0.03

 Moderate to severe	−10.0 (−19.2, −0.8)

 None to mild	reference

Characteristic	Coefficient (95% CI)	p-value

On-demand	reference

Chronic painb		0.03

Moderate to severe	−10.0 (−19.2, −0.8)

None to mild	reference


Subgroups	HR	95% CI	P Value

Patients with diabetes mellitus	0.36	0.14 to 0.90	0.03

Patients without diabetes mellitus	0.74	0.41 to 1.33	0.32

Patients with hypertension	0.57	0.36 to 0.92	0.02

Patients with hyperlipidemia	0.93	0.38 to 2.27	0.89

Patients with normal lipids	0.47	0.26 to 0.83	0.009

Patients with prior myocardial infarction	1.36	0.30 to 6.1	0.70

Patients with no prior myocardial infarction	0.57	0.35 to 0.94	0.02

Patients with major cardiac adverse events	0.30	0.08 to 1.13	0.07

Patients with no major cardiac adverse events	0.59	0.36 to 0.97	0.04

Subgroups

Patients with diabetes mellitus

Patients without diabetes mellitus

Patients with hypertension

Patients with hyperlipidemia

Patients with normal lipids

Patients with prior myocardial infarction

Patients with no prior myocardial infarction

Patients with major cardiac adverse events

Patients with no major cardiac adverse events


Nightly pain

Unbearable pain

Pain when changing position

Pain when walking

Pain when standing

Constant pain

Pain when stair climbing

Pain when sitting


•	‘I would prefer to see the same consultant in hospital, as I trust her already and would find it hard to build the same level of trust with someone else’

•	‘Continuity of care- New consultant may not read all information or interpret it differently’

•	‘A relationship of trust with your own consultant takes time to build and could never be done with a stranger that you meet now and again’

•	‘I’d prefer the above mainly for comfort and familiarity. I’ve shared my condition and stories enough times; having to repeat everything is pointless and counterproductive. It feels like an exercise in futility’

•	‘Continuity of care. I feel it would be best for me to have my care managed by someone who is familiar with me and can compare my symptoms with when I am well’

•	‘Over the past 5 years, I have had annual review as an outpatient and have seen a few different psychiatrists each time. I would prefer to be seen by one psychiatrist and also if admitted to hospital to see the same one’

•	‘Seeing the same doctor means you do not have to repeat your illness every time as this can be upsetting’

•	‘On one hand having the same consultant might give a sense of security. On the other hand, a different consultant having slightly different experiences, may also be a good thing-My personal view is that I would rather choose to have the same consultant’


Medium		Score

Ham's F-12	+10% FCS	180

DMEM/Ham's F-12 (1:1)	+10% FCS	170

Medium199	+10% FCS	165

DMEM	+10% FCS	165

McCoy's 5A	+10% FCS	140

Medium		Score

DMEM	+10% FCS	165

McCoy's 5A	+10% FCS	140


Author, Year, Citation	Sample size*	Respondents who reported the PtDA was balanced.n (%)	Did the PtDA include side-by-side display of evidence?	Did the PtDA include any side-by-side display?

Mathieu, Barratt et al., 2010 [14]	117	66 (57%)	no	no

Smith, Trevena et al., 2010 [15]	334	160 (48%)	no	no

Griffith, Fichter et al., 2008 [6]	106	17 (16%)	unclear	unclear

Spunt, Deyo et al., 1996 [16]	239	133 (56%)	unclear	unclear

Anderson, Carter et al., 2011 [17]	19	17 (89%)	no	yes

Watson, Hewitson et al., 2006 [18]	468	439 (94%)	no	yes

Drake, Engler-Todd et al., 1999 [19]	38	27 (71%)	yes	yes

Lalonde, O’Connor et al., 2004 [20]	16	13 (80%)	yes	yes

van Tol-Geerdink, Stalmeier et al., 2006 [21]	150	142 (95%)	yes	yes

van Tol-Geerdink, Leer et al., submitted [22]	153	147 (96%)	yes	yes

Author, Year, Citation	Sample size*	Respondents who reported the PtDA was balanced.n (%)	Did the PtDA include side-by-side display of evidence?	Did the PtDA include any side-by-side display?

Mathieu, Barratt et al., 2010 [14]	117	66 (57%)	no	no

Smith, Trevena et al., 2010 [15]	334	160 (48%)	no	no

Griffith, 	10	17 (16%	unclear	u

Author, Year, Citation	Sample size*	Respondents who reported the PtDA was balanced.n (%)	Did the PtDA include side-by-side display of evidence?	Did the PtDA include any side-by-side display?

Fichter et al., 2008 [6]	6	)		nclear

Spunt, Deyo et al., 1996 [16]	239	133 (56%)	unclear	unclear

Anderson, Carter et al., 2011 [17]	19	17 (89%)	no	yes

Watson, Hewitson et al., 2006 [18]	468	439 (94%)	no	yes

Drake, Engler-Todd et al., 1999 [19]	38	27 (71%)	yes	yes

Lalonde, O’Connor et al., 2004 [20]	16	13 (80%)	yes	yes

van Tol-Geerdink, Stalmeier et al., 2006 [21]	150	142 (95%)	yes	yes

van Tol-Geerdink, Leer et al., submitted [22]	153	147 (96%)	yes	yes


Position of the tapes	at 3 months after surgery	at 6 months after surgery	at one year after surgery

Proximal third of the urethra	3,92 %	9,81 %	9,81 %

The middle third of the urethra	88,23 %	82,35 %	82,35 %

Distal third	7,84 %	7,84 %	7,84 %


Semester	Nominees	Non-nominees

Weekday	Weekend	Weekday	Weekend

Semester 1	97	63	28	8

Semester 2	303	144	42	13

Semester	Nominees	Non-nominees

Weekday	Weekend	Weekday	Weekend

Semester	9	6	2	8


Test	Strain H-6	Alteromonas macleodii

Starch hydrolysis	+	+

Catalase	+	+

H2S production	+	+

Gelatin hydrolysis	+	+

Indole test	–	0

Methyl-red test	–	+

Voges-Proskauer test	–	–

Citrate utilization	–	0

Arginine utilization	+	0

Phenylalanine utilization	–	0

Glucose utilization	+	+

Lactose utilization	+	+

Sucrose utilization	+	+

Gram reaction	G−	G−

Test	Strain H-6	Alteromonas macleodii

Starch hyd		+

rolysis	+

Catalase	+	+

H2S production	+	+

Gelatin hydrolysis	+	+

Indole test	–	0

Methyl-red test	–	+

Voges-Proskauer test	–	–

Citrate utilization	–	0

Arginine utilization	+	0

Phenylalanine utilization	–	0

Glucose utilization	+	+

Lactose utilization	+	+

Sucrose utilization	+	+

Gram reaction	G−	G−


		2004	2005

		dry season	rainy season	global	dry season	rainy season	global

Data	Mean	0.390	0.311	0.351	0.166	0.212	0.190

	SD&	0.385	0.260	0.330	0.241	0.257	0.250

Kriging model		Ordinary	Ordinary	Ordinary	Ordinary	Universal	Ordinary

Transform data		No	No	No	No	No	No

Trend Removal		No	No	No	No	Yes	No

Searching Neighborhood	Radius (m)	9924.7	9509.9	9509.9	9924.7	9509.9	9924.7

	Angle	0	0	0	0	0	0

Prediction error measurements	Mean	0.021	0.005	0.012	0.005	0	-0.0004

	MSE#	0.435	0.302	0.338	0.157	0.113	0.102

	Average Stand. Error	0.4	0.282	0.308	0.144	0.11	0.102

	SMSE$	1.09	1.074	1.098	1.088	1.015	1.006


	Medical Costs	Costs per Hypoglycemia Event	Costs per Cardiovascular Events	Weight Gain Costs (transition costsa)	Total Costs (without transition costsa)

Metformin monotherapy	$24	$0	$141	$0	$165

Metformin+DPP-4i	$3524	$0	$330	$0	$3854

Metformin+DPP-4i + Basal insulin	$7170	$1	$366	$0	$7537

Metformin+SU	$40	$4	$441	$148	$486

Metformin+SU + Basal insulin	$3686	$1	$366	$0	$4054


Agricultural sector	Specific application areas	References

Agronomy/Horticulture	Crop protection	[2,33]

Cultivar selection & discrimination	[34,35,44]

Pesticide detection	[33,45–48]

Plant cell culture	[36]

Biotechnology processes	Monitoring	[49,50]

Botany	Floral odors	[37]

Plant identification	[30]

Plant volatiles detection	[30,38,39]

Taxonomic determinations	[30]

Cell culture	Plant growth	[36]

Chemistry	Chemical detection & identification	[51]

Classification	[52,53]

Ecology	Niche roles in ecosystem	[30]

Plant and animal species identification	[30]

Entomology	Detect insects or induced plant volatiles	[54–56]

Insect identification and plant damage	[57–61]

Environmental hazards	Ecosystem management	[30]

Explosive vapors	[62–64]

Health hazards monitoring	[5,65–70]

Toxic gas detection	[71–77]

Water contamination detection	[78–81]

Food production	Chemical contaminants	[82]

Microbial pathogens or toxins	[83,84]

Forestry/Silviculture	Classify/identify wood types	[30,85]

Forest health protection	[2,86]

Forest management	[30]

Industrial Processes	Process monitoring control	[87,88]

Formulation development	[89]

Quality control	[90]

Microbiology	Discrimination of strains	[91–95]

Identification of microbes	[96]

Microbial growth phases	[97]

Pathogen detection	[98]

Toxin production	[99]

Monitoring	Enzyme and protein activity	[100]

Humidity	[101,102]

Immunoglobulin levels	[103]

Oxygen levels	[104]

Plant volatiles	[39]

Physiological conditions	Disease effects on plant physiology	[31,32]

Fruits	[105]

Plant Pathology	Crop protection against bioterrorism	[2]

Disease detection and monitoring	[2,106–112]

Host identification	[30,85]

Host physiology (pathogenesis effects)	[31,32,105]

Host resistance	[113]

Pathogen identification	[2,106]

Post-harvest decay or rot detection	[114–118]

Wood decay fungi	[2,86,96,119,120]

Wood decay types	[2,86]

Waste management	Monitoring malodorous emissions	[23,121–125]

Wood science	Wood identifications	[30,85,126]

Botany	Plant identification	[30]

Plant volatiles detection	[30,38,39]

Taxonomic determinations	[30]

Cell culture	Plant growth	[36]

Chemistry	Chemical detection & identification	[51]

Classification	[52,53]

Ecology	Niche roles in ecosystem	[30]

Plant and animal species identification	[30]

Entomology	Detect insects or induced plant volatiles	[54–56]

Insect identification and plant damage	[57–61]

Environmental hazards	Ecosystem management	[30]

Explosive vapors	[62–64]

Health hazards monitoring	[5,65–70]

Toxic gas detection	[71–77]

Water contamination detection	[78–81]

Food production	Chemical contaminants	[82]

Microbial pathogens or toxins	[83,84]

Forestry/Silviculture	Classify/identify wood types	[30,85]

Forest health protection	[2,86]

Forest management	[30]

Industrial Processes	Process monitoring control	[87,88]

Formulation development	[89]

Quality control	[90]

Microbiology	Discrimination of strains	[91–95]

Identification of microbes	[96]

Microbial growth phases	[97]

Pathogen detection	[98]

Toxin production	[99]

Monitoring	Enzyme and protein activity	[100]

Humidity	[101,102]

Immunoglobulin levels	[103]

Oxygen levels	[104]

Plant volatiles	[39]

Physiological conditions	Disease effects on plant physiology	[31,32]

Fruits	[105]

Plant Pathology	Crop protection against bioterrorism	[2]

Disease detection and monitoring	[2,106–112]

Host identification	[30,85]

Host physiology (pathogenesis effects)	[31,32,105]

Host resistance	[113]

Pathogen identification	[2,106]

Post-harvest decay or rot detection	[114–118]

Wood decay fungi	[2,86,96,119,120]

Wood decay types	[2,86]

Waste management	Monitoring malodorous emissions	[23,121–125]

Wood science	Wood identifications	[30,85,126]


Pathways	Map B	No. of genes	No. of TFs

00010: Glycolysis/gluconeogenesis	Carbohydrate metabolism	57	14

00500: Starch and sucrose metabolism	Carbohydrate metabolism	32	12

00520: Amino sugar and nucleotide sugar metabolism	Carbohydrate metabolism	48	20

00620: Pyruvate metabolism	Carbohydrate metabolism	39	22

00030: Pentose phosphate pathway	Carbohydrate metabolism	25	14

00630: Glyoxylate and dicarboxylate metabolism	Carbohydrate metabolism	18	30

00250: Alanine, aspartate and glutamate metabolism	Amino acid metabolism	32	22

00290: Valine, leucine and isoleucine biosynthesis	Amino acid metabolism	11	30

00310: Lysine degradation	Amino acid metabolism	43	26

00230: Purine metabolism	Nucleotide metabolism	152	24

00590: Arachidonic acid metabolism	Lipid metabolism	77	21

00591: Linoleic acid metabolism	Lipid metabolism	40	13

00100: Steroid biosynthesisa	Lipid metabolism	18	17

00670: One carbon pool by folate	Metabolism of cofactors and vitamins	17	26

00790: Folate biosynthesisa	Metabolism of cofactors and vitamins	11	28

00900: Terpenoid backbone biosynthesisa	Metabolism of terpenoids and polyketides	13	22

00604: Glycosphingolipid biosynthesis-ganglio seriesa	Glycan biosynthesis and metabolism	15	19

00534: Glycosaminoglycan biosynthesis-heparan sulfate	Glycan biosynthesis and metabolism	24	25

Pathways	Map B	No. of genes

00010: Glycolysis/gluconeogenesis	Carbohydrate metabolism	57

00500: Starch and sucrose metabolism	Carbohydrate metabolism	32

00520: Amino sugar and nucleotide sugar metabolism	Carbohydrate metabolism	48

00620: Pyruvate metabolism	Carbohydrate metabolism	39

00030: Pentose phosphate pathway	Carbohydrate metabolism	25

00630: Glyoxylate and dicarboxylate metabolism	Carbohydrate metabolism	18

00250: Alanine, aspartate and glutamate metabolism	Amino acid metabolism	32

00290: Valine, leucine and isoleucine biosynthesis	Amino acid metabolism	11

00310: Lysine degradation	Amino acid metabolism	43

00230: Purine metabolism	Nucleotide metabolism	152

00590: Arachidonic acid metabolism	Lipid metabolism	77

00591: Linoleic acid metabolism	Lipid metabolism	40

00100: Steroid biosynthesisa	Lipid metabolism	18

00670: One carbon pool by folate	Metabolism of cofactors and vitamins	17

00790: Folate biosynthesisa	Metabolism of cofactors and vitamins	11

00900: Terpenoid backbone biosynthesisa	Metabolism of terpenoids and polyketides	13

00604: Glycosphingolipid biosynthesis-ganglio seriesa	Glycan biosynthesis and metabolism	15

00534: Glycosaminoglycan biosynthesis-heparan sulfate	Glycan biosynthesis and metabolism	24


Contig_ID	Log2_Fold_change	AdjP_value	2C FPKM	2 T FPKM	E-value	Protein families

c32642_g1_i1	-3.614	0.0009	3.1	0.3	0	Glycosyltransferase 8 family, Glycogenin subfamily

c38916_g2_i3	-3.232	0.0097	2.9	0.3	1.00E-83	Cyclin family, Cyclin AB subfamily

c44152_g1_i2	-2.667	0.0177	3.8	0.6	0	Cyclic nucleotide-gated cation channel family

c37946_g1_i2	-2.916	0.0244	4.1	0.6	1.00E-132	MAD2 family

c43673_g1_i5	-2.574	0.0313	4.8	0.8	0	Cytochrome P450 family

c44152_g1_i1	-2.545	0.0818	3.1	0.6	0	Cyclic nucleotide-gated cation channel family

c24995_g1_i1	-2.173	0.1794	2.8	0.7	0	WD repeat CDC20/Fizzy family

c25920_g1_i1	-2.094	0.2470	3.7	0.9	6.00E-162	NA

c33730_g1_i3	-1.879	0.3855	2.3	0.7	6.00E-96	HSF family, Class A subfamily

AdjP_value	2C FPKM	2 T FPKM	E-value	Protein families

0.0009	3.1	0.3	0	Glycosyltransferase 8 family, Glycogenin subfamily

0.0097	2.9	0.3	1.00E-83	Cyclin family, Cyclin AB subfamily

0.0177	3.8	0.6	0	Cyclic nucleotide-gated cation channel family

0.0244	4.1	0.6	1.00E-132	MAD2 family

0.0313	4.8	0.8	0	Cytochrome P450 family

0.0818	3.1	0.6	0	Cyclic nucleotide-gated cation channel family

0.1794	2.8	0.7	0	WD repeat CDC20/Fizzy family

0.2470	3.7	0.9	6.00E-162	NA

0.3855	2.3	0.7	6.00E-96	HSF family, Class A subfamily


	WC	BMI	PBF	HDL	Triglyceride	LDL	SBP	DBP

Females

 8 year old cohort	<.05	<.05	<.05	<.05	<.05

 11 year old cohort	<.05	<.05	<.05	<.05	<.05

 14 year old cohort		<.05	<.05

Males

 8 year old cohort	<.05	<.05	<.05

 11 year old cohort	<.05	<.05	<.05		<.05	<.05	<.05

 14 year old cohort	<.05	<.05	<.05	<.05	<.05	<.05

Females

8 year old cohort

11 year old cohort

14 year old cohort

Males

8 year old cohort

11 year old cohort

14 year old cohort


Causes of death	Number of deathsn (%)	Cause-Specific Mortality Rate (per 1000 people)

Ch. X – Diseases of the respiratory system, J00-J99	282 (37.1)	3187

Ch. IX – Diseases of the circulatory system, I00-I99	197 (25.9)	2227

Ch. V – Mental and behavioural disorders, F00-F99	81 (10.7)	916

Ch. VI – Diseases of the nervous system, G00-G99	59 (7.8)	669

Ch. I – Certain infectious and parasitic diseases, A00-B99	33 (4.3)	373

Ch. XVIII – Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified, R00-R99	28 (3.7)	317

Ch. XI – Diseases of the digestive system, K00-K93	16 (2.1)	181

Ch. II – Neoplasms, C00-D48	15 (2)	170

Ch. IV – Endocrine, nutritional and metabolic diseases, E00-E90	14 (1.8)	158

Ch. XIV – Diseases of the genitourinary system, N00-N99	10 (1.3)	113

Ch. XVII – Congenital malformations, deformations and chromosomal abnormalities, Q00-Q99	9 (1.2)	102

Ch. XX – External causes of morbidity and mortality, V01-Y98	8 (1.1)	90

Ch. III – Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, D50-D89	3 (0.4)	34

Ch. XIX – Injury, poisoning and certain other consequences of external causes, S00-T98	3 (0.4)	34

Ch. XIII – Diseases of the musculoskeletal system and connective tissue, M00-M99	2 (0.3)	23

Ch. XII – Diseases of the skin and subcutaneous tissue, L00-L99	0 (0)	NA

Ch. XVI - Certain conditions originating in the perinatal period, P00-P96	0 (0)	NA

Causes of death	Number of deathsn (%)

Ch. X – Diseases of the respiratory system, J00-J99	282 (37.1)

Ch. IX – Diseases of the circulatory system, I00-I99	197 (25.9)

Ch. V – Mental and behavioural disorders, F00-F99	81 (10.7)

Ch. VI – Diseases of the nervous system, G00-G99	59 (7.8)

Ch. I – Certain infectious and parasitic diseases, A00-B99	33 (4.3)

Ch. XVIII – Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified, R00-R99	28 (3.7)

Ch. XI – Diseases of the digestive system, K00-K93	16 (2.1)

Ch. II – Neoplasms, C00-D48	15 (2)

Ch. IV – Endocrine, nutritional and metabolic diseases, E00-E90	14 (1.8)

Ch. XIV – Diseases of the genitourinary system, N00-N99	10 (1.3)

Ch. XVII – Congenital malformations, deformations and chromosomal abnormalities, Q00-Q99	9 (1.2)

Ch. XX – External causes of morbidity and mortality, V01-Y98	8 (1.1)

Ch. III – Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, D50-D89	3 (0.4)

Ch. XIX – Injury, poisoning and certain other consequences of external causes, S00-T98	3 (0.4)

Ch. XIII – Diseases of the musculoskeletal system and connective tissue, M00-M99	2 (0.3)

Ch. XII – Diseases of the skin and subcutaneous tissue, L00-L99	0 (0)

Ch. XVI - Certain conditions originating in the perinatal period, P00-P96	0 (0)


Sample ID	ARW742C (TGg>TGt/c)ddPCRNEB Phusion® Preamplification	ARW742C (TGg>TGt/c)ddPCRInvitrogenTM PlatinumTM SuperFiTM Preamplification

Mutant Droplet Count	Wild-type Droplet Count	Percent Mutant	Mutant Droplet Count	Wild-type Droplet Count	Percent Mutant

JHU Pt 3	4	25067	0.016	38	33611	0.113

JHU Pt 7	0	19753	0.000	0	15958	0.000

PreamplifiedWild-type Genomic DNA	0	17573	0.000	0	37069	0.000

PreamplifiedNo Template Control	0	0	0.000	0	0	0.000

Non-AmplifiedWild-type Genomic DNA	0	31225	0.000	0	31225	0.000

Non-AmplifiedAR W742C Mutant Control DNA	10602	0	100	10602	0	100

Non-AmplifiedNo Template Control	0	0	0.000	0	0	0.000

Sample ID	ARW742C (TGg>TGt/c)ddPCRNEB Phusion® Preamplification	ARW742C (TGg>TGt/c)ddPCRInvitrogenTM PlatinumTM SuperFiTM Preamplification

Mutant Droplet Count	Wild-type Droplet Count	Percent Mutant	Mutant Droplet Count	Wild-type Droplet Count	Percent Mutant

PreamplifiedNo Template Control	0	0	0.000	0	0	0.000

Non-AmplifiedWild-type Genomic DNA	0	31225	0.000	0	31225	0.000

Non-AmplifiedAR W742C Mutant Control DNA	10602	0	100	10602	0	100

Non-AmplifiedNo Template Control	0	0	0.000	0	0	0.000


Domain	Principal cause	Number of patients

Neuromuscular	Parkinsonism syndrome	3

	Unexplained Ataxia	2

	Lower extremity weakness	7

Sensory	Dizziness or vertigo	2

	Visual impairment	4

	Peripheral neuropathy	3

Orthopedics	Osteoarthritis (including foot problems)	8

	Hip problems or deformity	6

CV causes*	Orthostatic hypotension	2

	Postprandial hypotension	1

	Vasovagal syndrome	2

	Carotid sinus hypersensitivity	1


	RECIST	CHOI	mCHOI	MASS

Progressive disease (MASS unfavourable response)	Increase in sum of longest target lesion diameters >20%.orDevelopment of new lesions.orUnequivocal non-target lesion progression.	Increase in lesion sizea > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule.	Increase in lesion sizea > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule.	Increase in lesion sizea > 20% without central necrosis.orDevelopment of new lesions.orNew intratumoral enhancing components.

Partial response (MASS favourable response)	>30% decrease in sum of longest target lesion diameters.	Decrease in target lesion CT enhancement (Hounsfield units) >15% or size >10%	Decrease in target lesion CT enhancement (Hounsfield units) >15% and size >10%	Decrease in lesion size >20%, central necrosis or reduction in attenuation >40 Hounsfield units

Complete response	Disappearance of all target lesions and resolution of lymphadenopathy (<10 mm).	Disappearance of all target lesions	Disappearance of all target lesions	Disappearance of all target lesions

Stable disease (MASS indeterminate response)	None of the above	None of the above	None of the above	None of the above

Progressive disease (MASS unfavourable response)

Partial response (MASS favourable response)

Complete response

Stable disease (MASS indeterminate response)

RECIST	CHOI	mCHOI	MASS

Increase in sum of longest target lesion diameters >20%.orDevelopment of new lesions.orUnequivocal non-target lesion progression.	Increase in lesion sizea > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule.	Increase in lesion sizea > 10%.orDevelopment of new lesions.orNew or enlarging intratumoral nodule.	Increase in lesion sizea > 20% without central necrosis.orDevelopment of new lesions.orNew intratumoral enhancing components.

>30% decrease in sum of longest target lesion diameters.	Decrease in target lesion CT enhancement (Hounsfield units) >15% or size >10%	Decrease in target lesion CT enhancement (Hounsfield units) >15% and size >10%	Decrease in lesion size >20%, central necrosis or reduction in attenuation >40 Hounsfield units

Disappearance of all target lesions and resolution of lymphadenopathy (<10 mm).	Disappearance of all target lesions	Disappearance of all target lesions	Disappearance of all target lesions

None of the above	None of the above	None of the above	None of the above


Whole sample size (N = 47)	Placebo	Perilla	Placebo	Perilla

Run In	Intake week 1-2	Intake week 3-4	p value (ANOVA)	Run In	Intake week 1-2	Intake week 3-4	p value (ANOVA)	Delta week 3-4 to run in	Delta week 3-4 to run in	Comparison between groups (95% CI)


				k-spaced AA pairs

Feature representation	Composition Vector	PSI-BLAST profile	Binary Encoding	adjacent pairs (dipeptides)	1-spaced pairs	......	p-spaced pairs	Total

Number of features	20	315	380	400	400	......	400	400(p+1)


Haplotype	Cases (percentage)	Controls (percentage)	OR (95% CI)a

z1 G-G-T-T-A	1,250 (49.4)	1,691 (48.2)	1.00 (reference)


Ingredient	Herb medicine	Object	Stimulus	Role	related pathway

1, 6-di-O-caffeoyl-β-D-glucopyranoside	Callicarpa nudiflora Hook	Platelet	ADP, AA	αIIbβ3, 5-HT, TXA2, platelet aggregation↓	PI3K/Akt/GSK3β, RhoA

Atractylenolide	Atractylodes macrocephala	Platelet	ADP, collagen, thrombin	platelet aggregation and secretion↓	p38, PI3K/Akt

Andrographolide	Andrographis paniculata	Platelet	Collagen	platelet aggregation, Ca2+, TxB2↓	eNOS/NO/sGC/cGMP, PI3K/Akt/p38/cPLA2, PLCγ2/DAG/PKC

platelet aggregation, Ca2+↓	eNOS/NO/sGC/cGMP, p38/ROS/IKKβ/NF-κB/ERK2

Gomisin J	Schisandra chinensis	EC	None	eNOS, NO↑	Ca2+/CaMI, PI3K/Akt

β-Elemene	Curcuma Wenyujin	EC	None	eNOS, NO↑	PI3K/Akt

Puerarin	Pueraria lobata	EC	TNF-α	eNOS, NO↑	ER/PI3K/Akt, CaMKII/AMPK

Tanshinone IIA	Salvia miltiorrhiza Bunge	Macrophage	Ox-LDL	TF↓	ROS/NF-κB

Platelet	None	Platelet activation↓	ERα/PI3K/Akt

Platelet	ADP	Platelet activation↓	ERK-2

Xuezhikang	Red yeast rice	Macrophage	Ox-LDL	TF↓, SOD↑	NOX/ROS/ERK1/2/NF-κB

Gypenoside XLIX	Gynostemma pentaphyllum	Macrophage	LPS	TF↓	PPAR-α

Salvianolic acid B	Salvia miltiorrhiza Bunge	EC	TNF-α	PAI-1↓	ERK1/2/AP-1 (NF-κB)


	Incremental cost	Incremental effect	ICER

	Mean; (95% bootstrap CI)	Mean; (95% bootstrap CI)

CBT versus TAU

Completers (N=152)

QALY (EQ-5D)	−2,061.9	−3,168.9	−954.9	0.01	−0.00	0.03	CBT dominant

EQ VAS	−2,073.2	−3,179.8	−966.6	6.19	3.63	8.75	CBT dominant

ITT (N=168)

QALY (EQ-5D)	−2,158.8	−3,357.1	−960.5	0.02	−0.00	0.03	CBT dominant

EQ VAS	−2,163.9	−3,363.8	−964.0	6.33	3.62	9.07	CBT dominant

PPA (N=154)

QALY (EQ-5D)	−2,368.9	−3,599.1	−1,138.6	0.02	−0.00	0.03	CBT dominant

EQ VAS	−2,372.4	−3,604.8	−1,140.0	6.58	3.83	9.33	CBT dominant

CBT versus RPT


Flavonoid	NGF	GDNF	BDNF

Flavanones

 Alpinetin	+++	++	+

 Hesperidin	—	+	—

 Naringenin	—	—	—

 Naringin	—	+++	—

 Neohesperidin	—	++	—

Flavones

 Apigenin	—	++	—

 Baicalein	—	—	—

 Luteolin	++++	++++	++

 Tangeretin	++	—	—

 Wogonin	—	—	—

Aurones

 Sulfuretin	—	++	—

Dihydrochalcones

 Phloretin	—	—	—

Flavonols

 Silybin	++++	—	+

Chalcones

 Cardamonin	+	++	—

Isoflavones

 Calycosin	+++	++++	+++

 Calycosin-7-O-glc	+++	++	—

 Daidzein	—	—	—

 Formononetin	—	—	—

 Genistein	++++	++++	++

 Genistin	—	—	—

 Puerarin	+	+++	—

Flavones

 (−)-Catechin	—	—	+

 (−)-Epicatechin	—	—	—

Flavonols

 Fisetin	+++	—	+

 Galangin	—	++	—

 Hyperin	—	—	—

 Icariin	—	—	+

 Isorhamnetin	++++	++++	+++

 Kaempferol	+	+	+

 Quercetin	—	+	—

 RNFG	—	++	—

 173-estradiol	++++	++++	+++

Flavonoid	NGF	GDNF	BDNF

Genistin	—	—	—

Puerarin	+	+++	—

Flavones

(−)-Catechin	—	—	+

(−)-Epicatechin	—	—	—

Flavonols

Fisetin	+++	—	+

Galangin	—	++	—

Hyperin	—	—	—

Icariin	—	—	+

Isorhamnetin	++++	++++	+++

Kaempferol	+	+	+

Quercetin	—	+	—

RNFG	—	++	—

173-estradiol	++++	++++	+++


Gene ID	ENSEMBL Gene ID	Gene name	Base Mean	Fold Change (log2)	p-adj

VIM	ENSECAG00000004216	vimentin	101,873.95	0.49	0.0846

LUM	ENSECAG00000018248	lumican	93,834.08	1.21	0.0000

EEF1A1	ENSECAG00000020363	eukaryotic translation elongation factor 1 alpha 1	80,865.77	0.35	0.4978

FN1	ENSECAG00000000701	fibronectin 1	76,204.43	− 0.03	0.9131

COL3A1	ENSECAG00000024769	collagen type III alpha 1	71,782.03	−0.28	0.3120

COL1A2	ENSECAG00000024740	collagen type I alpha 2	68,527.63	0.03	0.9444

ACTG1	ENSECAG00000018600	actin gamma 1	67,827.73	0.59	0.1648

DCN	ENSECAG00000020413	decorin	66,957.05	0.72	0.0000

CLU	ENSECAG00000007010	clusterin	60,592.80	0.54	0.3689

CTSK	ENSECAG00000019087	cathepsin K	50,743.84	−0.01	0.9822

PSAP	ENSECAG00000021672	prosaposin	42,671.36	−0.71	0.0123

COL6A3	ENSECAG00000020887	collagen type VI alpha 3 chain	39,357.71	−0.81	0.0000

AHNAK	ENSECAG00000014229	AHNAK nucleoprotein	32,777.16	−1.03	0.0004

TPT1	ENSECAG00000018348	tumor protein, translationally-controlled 1	32,069.02	0.86	0.0000

RPL4	ENSECAG00000023179	ribosomal protein L4	28,412.14	0.55	0.0555

ANXA1	ENSECAG00000015794	annexin A1	28,358.48	1.22	0.0000

HSP90AA1	ENSECAG00000018948	heat shock protein 90 alpha family class A member 1	27,249.39	0.36	0.5410

ASPN	ENSECAG00000007047	asporin	27,102.67	1.44	0.0000

EIF4G2	ENSECAG00000014700	eukaryotic translation initiation factor 4 gamma 2	25,563.63	1.26	0.0000

HSPA8	ENSECAG00000013510	heat shock protein family A (Hsp70) member 8	23,372.98	−0.02	0.9496

HTRA1	ENSECAG00000009990	HtrA serine peptidase 1	23,322.81	−0.18	0.7559

APP	ENSECAG00000021011	amyloid beta precursor protein	21,959.94	−0.08	0.7687

CLTC	ENSECAG00000019077	clathrin heavy chain	21,758.80	0.44	0.1597

CTNNB1	ENSECAG00000006949	catenin beta 1	21,082.51	0.57	0.0512

FAP	ENSECAG00000011790	fibroblast activation protein alpha	20,454.17	1.72	0.0000

Gene ID	ENSEMBL Gene ID	Gene name

VIM	ENSECAG00000004216	vimentin

LUM	ENSECAG00000018248	lumican

EEF1A1	ENSECAG00000020363	eukaryotic translation elongation factor 1 alpha 1

FN1	ENSECAG00000000701	fibronectin 1

COL3A1	ENSECAG00000024769	collagen type III alpha 1

COL1A2	ENSECAG00000024740	collagen type I alpha 2

ACTG1	ENSECAG00000018600	actin gamma 1

DCN	ENSECAG00000020413	decorin

CLU	ENSECAG00000007010	clusterin

CTSK	ENSECAG00000019087	cathepsin K

PSAP	ENSECAG00000021672	prosaposin

COL6A3	ENSECAG00000020887	collagen type VI alpha 3 chain

AHNAK	ENSECAG00000014229	AHNAK nucleoprotein

TPT1	ENSECAG00000018348	tumor protein, translationally-controlled 1

RPL4	ENSECAG00000023179	ribosomal protein L4

ANXA1	ENSECAG00000015794	annexin A1

HSP90AA1	ENSECAG00000018948	heat shock protein 90 alpha family class A member 1

ASPN	ENSECAG00000007047	asporin

EIF4G2	ENSECAG00000014700	eukaryotic translation initiation factor 4 gamma 2

HSPA8	ENSECAG00000013510	heat shock protein family A (Hsp70) member 8

HTRA1	ENSECAG00000009990	HtrA serine peptidase 1

APP	ENSECAG00000021011	amyloid beta precursor protein

CLTC	ENSECAG00000019077	clathrin heavy chain

CTNNB1	ENSECAG00000006949	catenin beta 1

FAP	ENSECAG00000011790	fibroblast activation protein alpha


Treatment category

Cat I	Treatment for new patients with first-line anti-TB drugs (2 months of INH, RIF, EMB, PZA/4 months of INH, RIF)

Cat II	Re-treatment regimen with first-line anti-TB drugs (2 months of STR, INH, RIF, EMB, PZA/1 month of INH, RIF, EMB, PZA/3 months of INH, RIF, EMB)

New	A patient who has never had treatment for TB or who has taken anti-TB drugs for <1 month

Close contact	Close contacts of MDR-TB patients who develop active TB

Failure	A patient previously treated for TB who is started on a re-treatment regimen after previous treatment has failed

Relapse	A patient who was previously declared cured or treatment completed and is diagnosed with bacteriologically-positive (sputum smear or culture) TB

Standard MDR-TB regimen	6 months of AMK, PZA, LFX, ETH, DCS/18 months of PZA, LFX, ETH, DCS a

Treatment category

Standard MDR-TB regimen	6 months of AMK, PZA, LFX, ETH, DCS/18 months of PZA, LFX, ETH, DCS a


Contact Stress, GPa	Rolling Time, h	Rolling Speed, rpm	Condition

2.5	12, 24	1000	dry

3.0

Contact Stress, GPa	Rolling Time, h	Rolling Speed, rpm	Condition

2.5		1	dry

3.


Effect size	Point estimatefreqpost mean post median	Percentile bootstrap	Bias-corrected bootstrap	Bayesian equal-tail credibilityintervals	Bayesian HPD credibilityintervals


Segmental LV wall	Endocardial (%)	Middle (%)	Epicardial (%)

Preoperative	Postoperative	P-value	Preoperative	Postoperative	P-value	Preoperative	Postoperative	P-value


	Screening	Randomization	3 monthlyFU	6 monthlyFU	End of study

25(OH)D3 serum levels		X	X(when 25(OH)D3 levels >80 ng/ml and study drug temporarily interrupted)	X

Blood sample for DNA analysis		X

Hemoglobin, Hematocrit	X				X

WBC count and differentiation	X			X	X

RBC count	X				X

Platelet count	X				X

Renal function (creatinine)	X				X

Liver function (AF, ALT, gamma-GT, LDH)	X				X

Serum calcium	X		X		X

Serum phosphate	X		X		X

Albumin	X				X

24 h urine calcium					X


Author, date	No. Participants = n	Avg age at start	Cast changed	Avg days in casts - ‘fast’ group	Tenotomy rate	Follow up	Comment

Morecuende, 2005	230(non-random)	Not stated	5 days	30	85%	Study ran over 11 years	Older study, NR sample

Harnett, 2011	40(RCT)	21 days	3 / week	16	79%	Min 6 mthsAve 8 mths	Youngest children

Xu, 2011	26(RCT)	92 days	2 / week	20.6	87%	2–6 years	Manipulation time of 2 min

Ullah, 2014	28(RCT)	18 weeks	2 / week	23.3	80%	Not reported

Elgohary, 2015	41(RCT)	11 weeks (SD 7)	2 / week	18.1 (SD 3)	91%	12–48 mths	Relapse rate 15% both groups

RCT data summary	RCTsn = 135	11 weeks	2/week	19.5 days	84% average	1 year(3 RCTs)	Young infants, 2 min. Stretch


Variable	Coefficient	S.E.	p-value	OR	95%CI


	Bacteria	Methanogens

Community	Similarity	Pseudo- F	P-value	Similarity	Pseudo- F	P-value

Treatment effect		4.54	0.007		9.06	0.003

Pairwise comparisons

 CON versus CHI	59.5	2.33	0.046	76.0	1.09	0.360

 CON versus IVY	73.9	1.62	0.118	62.4	3.10	0.024

 CHI versus IVY	60.1	2.17	0.048	60.7	7.00	0.003


Code Level 3	Label level 3	Assigned land use type

111	Continuous urban fabric	Urban

112	Discontinuous urban fabric	Urban

121	Industrial or commercial units	Urban

122	Road and rail networks and associated land	Urban

123	Port areas	Urban

124	Airports	Urban

131	Mineral extraction sites	Urban

132	Dump sites	Urban

133	Construction sites	Urban

141	Green urban areas	Urban

142	Sport and leisure facilities	Urban

211	Non-irrigated arable land	Arable

212	Permanently irrigated land	Arable

213	Rice fields	Arable

221	Vineyards	Arable

222	Fruit trees and berry plantations	Arable

223	Olive groves	Arable

231	Pastures	Grassland

241	Annual crops associated with permanent crops	Arable

242	Complex cultivation patterns	Arable

243	Land principally occupied by agriculture, with significant areas of natural vegetation	Grassland

244	Agro-forestry areas	Forest

311	Broad-leaved forest	Forest

312	Coniferous forest	Forest

313	Mixed forest	Forest

321	Natural grasslands	Grassland

322	Moors and heathland	Grassland

323	Sclerophyllous vegetation	Grassland

324	Transitional woodland-shrub	Forest

333	Sparsely vegetated areas	Grassland


Variables	Crude ORs	Model 1	Model 2	Model 3


Function	P-value	No. of Genes

Cellular movement	2.10E-35 to 3.60E-05	584

Cell death	1.99E-30 to 3.56E-05	853

Cellular development	2.08E-29 to 3.43E-05	730

Cellular growth and proliferation	3.01E-28 to 2.40E-05	912

Cellular assembly and organization	1.24E-15 to 3.32E-05	460

Function	P-value	No. of Genes

Cellular assembly and organization	1.24E-15 to 3.32E-05	460


Food Groups	Factor I Meat–Instant Food Dietary Pattern	Factor II Vege–Seafood Dietary Pattern	Factor III Cereal–Dairy Dietary Pattern

Milk	−0.174	0.047	0.597

Dairy products	0.038	0.058	0.634

Eggs	0.471	0.131	0.154

Meat	0.552	0.265	−0.037

Organ meats	0.313	0.127	0.036

Legumes/soy products	0.331	0.354	0.146

Seafood	0.312	0.400	0.070

Light-colored vegetables	−0.055	0.815	0.078

Dark-colored vegetables	−0.084	0.841	0.080

Fruit	−0.063	0.440	0.355

Vegetables with oil/dressing	0.278	0.569	−0.053

Rice/flour products	0.295	−0.011	0.521

Whole grains	−0.039	0.089	0.441

Root crops	0.126	0.241	0.397

Refined dessert	0.327	0.226	−0.079

Jam/honey	0.317	−0.066	0.453

Sugary drinks	0.524	−0.173	0.154

Rice/flour cooked in oil	0.405	0.011	0.238

Deep-fried food	0.674	0.111	−0.030

Instant noodle	0.397	−0.115	−0.009

Processed food	0.611	0.051	0.053

Sauce	0.549	0.076	−0.035


	Cases	sCD157 <31.02 ng/ml	sCD157 ≥31.02 ng/ml	P value*

MPM, n	61	30	31

Age at diagnosis, y				0.062

 mean ± SD		73.07 ± 10,46	77.39 ± 6.76

 median (range)		73.50 (52–94)	79.00 (61–89)

Sex				0.106

 Male	40	23	17

 Female	21	7	14

Histologic subtype				0.951

 Epithelioid	47	23	24

 Sarcomatoid	5	3	2

 Biphasic	2	1	1

 NOSa	7	3	4

Cytology				0.359

 negative	21	13	8

 positive	21	9	12

 suspicious	19	8	11

PMNb (n = 54)				0.516

 <10 cells × 10 (HPF, 200×)c	36	17	19

 10–50 cells × 1 (HPF, 200×)	14	8	6

 >50 cells × 10 (HPF, 200×)	4	1	3

CD157 expression in biopsy tissues (n = 29)				0.06

 H-score <110	11	8	3

 H-score ≥110	18	6	12

Follow-up (n = 54)				0.005

 DODd	43	17	26

 AWDe	11	10	1


Partition number	Cluster number	BRCA1	BRCA2	Number of genes selected

1	1	0	4	80

	2	7	4

2	1	7	4	110

	2	0	4

3	1	5	3	73

	2	2	5

4	1	6	0	61

	2	1	8


		Single methods	Combined method

Case	Histology (Lauren)	IHC (Score)	SISH (≥ 2.0/< 2.0)	IHC (Score)	SISH (≥ 2.0/< 2.0)


	pN0 and pN1	pN2 and pN3	p-value

Percentage of positive tumors cells	47.12 +/- 29,.3	55.62 +/- 26.33	0.068

Staining intensity	1.22 +/- 0.82	1.43 +/- 0.75	0.036*


Variables	Name and source of the original scales and items	α	Items (n)

Socio-demographic factorsa		18

Health behaviour

 Physical activity	Health Questionnaire age 18–64 years [29]	–	1

 Dietary habits	Food Frequency Questionnaire [30]	–	15

 Smoking	Health Questionnaire age 18–64 years [7]	–	2

 Alcohol consumption	AUDIT-C [31, 32]	–	3

Health status

 General health status	Survey in vocational schools in Bielefeld [36]	–	1

 Diseases and complaints	Work Ability Index – Questionnaire [33]	–	6

 Self-efficacy	Self-efficacy scale [24]	0.85	10

 Irritation	Irritation scale [22]	0.88	8

Occupational situation and prospects

 Job satisfaction	COPSOQ: German standard version [23, 34]	0.81	7

 Job strain and prospects	Additional questions (e.g., taking into account the current work situation, do you want to stay in this profession for the next five years?)	–	3

Variables	Name and source of the original scales and items	α	Items (n)

alth behaviour

Physical activity	Health Questionnaire age 18–64 years [29]	–	1

Dietary habits	Food Frequency Questionnaire [30]	–	15

Smoking	Health Questionnaire age 18–64 years [7]	–	2

Alcohol consumption	AUDIT-C [31, 32]	–	3

Health status

General health status	Survey in vocational schools in Bielefeld [36]	–	1

Diseases and complaints	Work Ability Index – Questionnaire [33]	–	6

Self-efficacy	Self-efficacy scale [24]	0.85	10

Irritation	Irritation scale [22]	0.88	8

Occupational situation and prospects

Job satisfaction	COPSOQ: German standard version [23, 34]	0.81	7

Job strain and prospects	Additional questions (e.g., taking into account the current work situation, do you want to stay in this profession for the next five years?)	–	3


	Coefficient	Standard Error

HIV-infected

For Log IP-10

Gender	0.153	0.101

Age	0.005	0.005

Weight	0.002	0.003

Co-morbidity	-0.078	0.098

For log sCD14

Gender	0.074	0.056

Age	0.002	0.002

Weight	0.002	0.003

Co-morbidity	-0.003	0.055

HIV-uninfected

For Log IP-10

Gender	-0.098	0.148

Age	-0.007	0.008

Weight	0.005	0.009

For log sCD14

Gender	-0.074	0.057

Age	-0.001	0.002

Weight	0.001	0.003


PROCEDURE	ONCOLOGIC RESULTS

RARC*	equivalent lymph node yields	comparable overall and recurrence-free survival	similar positive surgical margins in ≤ T2 disease

RAPN§	comparable margin status	equivalent local recurrence rates

RALNU#	studies with long-term follow-up are needed


Comorbidity	ICD codes

Heart failure	ICD-8:	427, 428

ICD-10:	I42, I50, I110, J819

Ischaemic heart disease	ICD-8:	411, 412, 413, 414

ICD-10:	I20, I23, I24, I25,

Anemia	ICD-8:	280-285

ICD-10:	D60-D69

Cancer	ICD-8:	140-209

ICD-10:	C00-C97

Chronic obstructive pulmonary disease	ICD-8:	490, 491, 492

ICD-10:	J42, J44

Atrial fibrillation	ICD-8:	427.4

ICD-10:	I48

Acute myocardial infarction	ICD-8:	410

ICD-10:	I21, I22

Peripheral arterial disease	ICD-8:	443

ICD-10:	I70, I74

Diabetes	ICD-8:	250

ICD-10:	E10-E14

Hypertension	ICD-8:	400, 401

ICD-10:	I109, I119, !959, I270, I951


Group Examined (ICD-9 Code)	0 μg Organic-Hg (%) (Reference Dose)	12.5 μg Organic-Hg (%)	25 μg Organic-Hg (%)	37.5 μg Organic-Hg (%)	Odds Ratio per μg Organic-Hg (95% CI) (p-value)

Febrile Seizure Cases (780.3)	218 (5.2)	60 (1.4)	3432 (81.5)	499 (11.9)	1 (0.993–1.003) (0.53)


Advantages	Shortcomings

Available anywhere on the earth in any weather conditions for outdoor measurements at no cost	High cost of professional equipment

Tri-dimensional positioning with centimeter accuracy (Real Time Kinematics, RTK mode)	Not fully validated for gait analysis yet

No space restriction: freedom in the path selection, including uphill/downhill locomotion.	Limited time windows (2–4 h per day)

Free living conditions, i.e close to real life	One body segment measured only (head): Because of mandatory constant satellite access, the antenna must not be obstructed by body parts.

Unlimited number of consecutive strides: limited only by the memory capacity of the receiver and the duration of the batteries.	Outdoor analysis: difficult to standardize environmental conditions (weather, terrain).

	Not fully miniaturized (cumbersome antenna).

Advantages

Available anywhere on the earth in any weather conditions for outdoor measurements at no cost

Tri-dimensional positioning with centimeter accuracy (Real Time Kinematics, RTK mode)

No space restriction: freedom in the path selection, including uphill/downhill locomotion.

Free living conditions, i.e close to real life

Unlimited number of consecutive strides: limited only by the memory capacity of the receiver and the duration of the batteries.

Shortcomings

High cost of professional equipment

Not fully validated for gait analysis yet

Limited time windows (2–4 h per day)

One body segment measured only (head): Because of mandatory constant satellite access, the antenna must not be obstructed by body parts.

Outdoor analysis: difficult to standardize environmental conditions (weather, terrain).

Not fully miniaturized (cumbersome antenna).


Operation (Pipette-dependence modea)	Purpose	Details

PF	1	Input (I-mode)	Liquid charging into MMV wells	Figure 1c

2	Output (O-mode)	a. Transfer	Complete ejection of liquid in wells	Figure 1b and Additional file 6: Figure S5

b. Washing

3	Square transfer (S-mode)	Fractional volume transfer	Additional file 2: Figure S1

4	Z-direction transfer (Z-mode)	Normal transfer of liquid into wells	Figure 1b and Additional file 5: Figure S4

5	X-direction transfer (X-mode)	Division of liquid in all wells	Additional file 7: Figure S6

6	Magnetic beads transfer (M-mode)	a. Beads recovery	Beads recovery	Additional file 8: Figure S7

b. Division of liquid	Division of liquid in all wells	Additional file 9: Figure S8

7	Filtering (F-mode)	Filter-selective transfer	Figure 2a

PD	8	Pipette-dependent transfer (P-mode)	a. Manual	Manual transfer of liquid or beads	Additional file 10: Figure S9

b. Robotic	Robotic transfer of liquid or beads	Additional file 3: Figure S2

PF	2	Output (O-mode)	a. Transfer	Complete ejection of liquid in wells	Figure 1b and Additional file 6: Figure S5

b. Washing

3	Square transfer (S-mode)	Fractional volume transfer	Additional file 2: Figure S1

4	Z-direction transfer (Z-mode)	Normal transfer of liquid into wells	Figure 1b and Additional file 5: Figure S4

5	X-direction transfer (X-mode)	Division of liquid in all wells	Additional file 7: Figure S6

6	Magnetic beads transfer (M-mode)	a. Beads recovery	Beads recovery	Additional file 8: Figure S7

b. Division of liquid	Division of liquid in all wells	Additional file 9: Figure S8

7	Filtering (F-mode)	Filter-selective transfer	Figure 2a

PD	8	Pipette-dependent transfer (P-mode)	a. Manual	Manual transfer of liquid or beads	Additional file 10: Figure S9

b. Robotic	Robotic transfer of liquid or beads	Additional file 3: Figure S2


Gene	Sequence (5′-3′)	Product size (bp)

IL-6	For: CCTGACCCAACCACAAATGC	646

Rev: CCTTAAAGCTGCGCAGAATGA

IL-8	For: CTTTCCACCCCAAATTTATCAAAG	264

Rev: AGAGCTCTCTTCCATCAGAAAGCT

GAPDH	For: ACACCCACTCCTCCACCTTT	199

Rev: TAGCCAAATTCGTTGTCATACC


Before SS exposure on PND59	After SS exposure on PND59


	EAPs for sensing

	pros	cons

ionic EAPs

 conducting polymers	chemical stability, miniaturization, facile fabrication process, low-cost, low-weight, biocompatibility, soft, multiformable (sheet, film, tubular, trilayer), response to mechanical, electrical, chemical and thermal stimulation	insufficient adhesion onto substrate, fragile upon mechanical and thermal loading

 ionic polymer–metal composites	low-weight, biocompatibility, miniaturization, soft, large produced voltage signal, sensitive to large bending deformation, ability to work in wet environments	hysteresis, sensitive to moisture and temperature during operation, operation limited to low temperature due to liquid electrolyte, slow response

 carbon nanotubes	high surface area to volume, high sensitivity, miniaturization, directional mechanical and electrical properties	expensive, slow response, difficult to control intrinsic properties during fabrication

electronic EAPs

 dielectric elastomers	large sensing range, low-cost, light-weight, stability in many working cycles, and capability as self-sensing actuators	defect-sensitive, rare for stress measurement, not sensitive to compression in normal direction, may be affected by temperature

 liquid-crystal elastomers	potential for high strain changes, potential high sensitivity to strain	complex and expensive synthesis and processing of the materials

 piezoelectric polymers	wide bandwidth, fast electromechanical response, relatively low-power requirements, high generative forces	relatively low output performance originating from charge dissipation. Some materials need to be stretched and poled to gain higher output

ionic EAPs

conducting polymers

ionic polymer–metal composites

carbon nanotubes

electronic EAPs

dielectric elastomers

liquid-crystal elastomers

piezoelectric polymers

EAPs for sensing

pros	cons

ionic EAPs

chemical stability, miniaturization, facile fabrication process, low-cost, low-weight, biocompatibility, soft, multiformable (sheet, film, tubular, trilayer), response to mechanical, electrical, chemical and thermal stimulation	insufficient adhesion onto substrate, fragile upon mechanical and thermal loading

low-weight, biocompatibility, miniaturization, soft, large produced voltage signal, sensitive to large bending deformation, ability to work in wet environments	hysteresis, sensitive to moisture and temperature during operation, operation limited to low temperature due to liquid electrolyte, slow response

high surface area to volume, high sensitivity, miniaturization, directional mechanical and electrical properties	expensive, slow response, difficult to control intrinsic properties during fabrication

electronic EAPs

large sensing range, low-cost, light-weight, stability in many working cycles, and capability as self-sensing actuators	defect-sensitive, rare for stress measurement, not sensitive to compression in normal direction, may be affected by temperature

potential for high strain changes, potential high sensitivity to strain	complex and expensive synthesis and processing of the materials

wide bandwidth, fast electromechanical response, relatively low-power requirements, high generative forces	relatively low output performance originating from charge dissipation. Some materials need to be stretched and poled to gain higher output


Drug resistant plasmid Name	Antimicrobial drug	Drug resistance plasmid MIC (ug/ml)	Empty vector MIC (ug/ml)	Fold increase

pAMP	ampicillin	16	4	4

pAMP	piperacillin	3	2	1.5

pAMP	cefotaxime	<.25	<.25	0

pAMP	ceftazidime	<.5	<.5	0

pAMP	cefepime	0.064	0.094	0.68

pAMP	Aztreonam	0.19	0.125	1.5

pAMP	Imipenem	0.25	0.25	0

pCIP	ciprofloxacin	0.125	<0.002	>62.5

pCIP	levofloxacin	0.38	0.012	31.7

pCIP	Ampicillin	6	4	1.5

pCIP	piperacillin	3	2	1.5

pCIP	ceftazidime	<.5	<.5	0

pCIP	cefotaxime	<.25	<.25	0

pCIP	cefepime	0.125	0.094	1.3

pCIP	Imipenem	0.25	0.25	0

pTMP	trimethoprim	>32	0.124	>258

pTMP	trimethoprim- sulfamethoxazole	0.5	0.064	7.8

pAZT	Aztreonam	12	0.125	96

pAZT	cefepime	1	0.094	10.6

pAZT	ceftazidime	16	0.5	32

pAZT	piperacillin	12	2	6

pSXT	trimethoprim-sulfamethoxazole	1	0.064	15.6

pSXT	trimethoprim	>32	0.125	>256

pPRP:1B	ciprofloxacin	0.125	0.016	7.8

pPRP:1B	levofloxacin	0.25	0.047	5.3

Drug resistant plasmid Name	Antimicrobial drug	Drug resistance plasmid MIC (ug/ml)	Empty vector MIC (ug/ml)	Fold increase

pAMP	Aztreonam	0.19	0.125	1.5

pAMP	Imipenem	0.25	0.25	0

pCIP	ciprofloxacin	0.125	<0.002	>62.5

pCIP	levofloxacin	0.38	0.012	31.7

pCIP	Ampicillin	6	4	1.5

pCIP	piperacillin	3	2	1.5

pCIP	ceftazidime	<.5	<.5	0

pCIP	cefotaxime	<.25	<.25	0

pCIP	cefepime	0.125	0.094	1.3

pCIP	Imipenem	0.25	0.25	0

pTMP	trimethoprim	>32	0.124	>258

pTMP	trimethoprim- sulfamethoxazole	0.5	0.064	7.8

pAZT	Aztreonam	12	0.125	96

pAZT	cefepime	1	0.094	10.6

pAZT	ceftazidime	16	0.5	32

pAZT	piperacillin	12	2	6

pSXT	trimethoprim-sulfamethoxazole	1	0.064	15.6

pSXT	trimethoprim	>32	0.125	>256

pPRP:1B	ciprofloxacin	0.125	0.016	7.8

pPRP:1B	levofloxacin	0.25	0.047	5.3


Primers	Sequences	Denaturation	annealing	Cycles	PCR products

HGF: ForwardReverse	5'-CAGAGGGACAAAGGAAAAGAA-3'5'-GCAAGTGAATGGAAGTCCTTTA-3'	94°C, 15s	58°C, 60s	40	167 bp

KGF: ForwardReverse	5'-GAACAAGGAAGGAAAACTCTATGCAA-3'5'-AAGTGGGCTGTTTTTTGTTCTTTCT-3'	94°C, 15s	60°C, 60s	40	201 bp

HGF-R: ForwardReverse	5'-GTTTACTTGTTGCAAGGGAGAAGACT-3'5'-TAGGGTGCCAGCATTTTAGCA-3'	94°C, 15s	58°C, 60s	40	88 bp

KGF-R: ForwardReverse	5'-TTAAGCAGGAGCATCGCATTG-3'5'-AACATCCAGGTGGTACGTGTGAT-3'	94°C, 15s	60°C, 60s	40	151 bp

Ubiquitin-c: ForwardReverse	5'-CACTTGGTCCTGCGCTTGA-3'5'-TTTTTTGGGAATGCAACAACTTT-3'	94°C, 15s	60°C, 60s	40	105 bp

Primers	Sequences	Denaturation	annealing	Cycles	PCR products

Ubiquitin-c: ForwardReverse	5'-CACTTGGTCCTGCGCTTGA-3'5'-TTTTTTGGGAATGCAACAACTTT-3'	94°C, 15s	60°C, 60s	40	105 bp


Base value	Esmolol group (n = 75)	Control group (n = 76)	t/χ2	P

Male, n (%)	54 (72.0)	53 (69.7)	0.094	0.760

APACHE-II score, mean ± standard deviation	24.20 ± 7.66	25.46 ± 7.83	−0.999	0.319

Base value	Esmolol group (n = 75)	Control group (n = 76)	t/χ2	P

HR, mean ± standard deviation	125.04 ± 13.28	127.21 ± 13.88	−0.982	0.328

MAP, mean ± standard deviation	74.71 ± 7.28	75.89 ± 6.61	−1.051	0.295

CVP, mean ± standard deviation	12.45 ± 3.16	11.99 ± 3.35	0.881	0.380

IS, mean ± standard deviation	10.99 ± 2.08	11.11 ± 1.81	−0.374	0.709

Lac, mean ± standard deviation	8.98 ± 3.09	9.74 ± 4.05	−1.301	0.195

P(va)CO2, mean ± standard deviation	9.54 ± 3.89	10.12 ± 3.52	−0.947	0.345

ScvO2, mean ± standard deviation	0.77 ± 0.06	0.78 ± 0.06	−0.537	0.592


True/False item	Correct answer	% correct*	True/False item	Correct answer	% correct*

HIV/AIDS KNOWLEDGE	 	 	OVERDOSE KNOWLEDGE

When a couple decides that they are ONLY going to have sex with each other, they no longer need to use condoms to prevent HIV.	F	66.9 (62.1, 71.8)	Causing physical pain will help keep someone who is overdosing conscious or alive.	F	36.9 (31.9, 41.9)

The fewer sex partners you have in your life, the less likely you are to get HIV.	T	66.0 (61.2, 70.9)	Fatal ODs are more likely to happen when people use alone.	T	89.5 (86.4, 92.6)

People can still transmit the HIV/AIDS virus even if they test negative for the virus.	T	45.2 (40.1, 50.3)	People are more likely to have an OD if they use soon after getting out of a government center, prison, or detoxification program.	T	84.8 (81.1, 88.5)

Most people who have HIV know they have it.	F	52.1 (46.9, 57.2)	Most heroin OD deaths happen very quickly, in less than 15 minutes after taking the drugs.	F	9.8 (6.7, 12.8)

HEPATITIS KNOWLEDGE	 	 	It is easy to tell the difference between a “heavy nod” and a heroin overdose.	F	10.1 (7.0, 13.2)

Hepatitis can cause liver cancer.	T	72.1 (67.5, 76.7)	Sweating and anxiety are signs of a heroin OD.	F	58.0 (52.9, 63.1)

HIV is easier to transmit than hepatitis.	F	46.4 (41.3,51.6)	Injecting water can slow or reverse the effects of an opioid overdose	F	30.5 (25.7, 35.2)

You will be able to recognize if any individual is infected with hepatitis.	F	40.9 (35.8, 46.0)	Someone who is overdosing should be immediately placed on their back.	F	18.3 (14.3, 22.3)

Most people infected with hepatitis know that they have the disease.	F	46.4 (41.2, 51.6)	Naloxone is a medication for reversing the effects of a heroin OD.	T	47.7 (42.4, 53.0)

Drinking alcohol worsens the course of hepatitis C.	T	84.2 (80.4, 87.9)	Naloxone must be injected into a vein.	F	26.9 (22.2, 31.7)

You are more likely to get hepatitis B than hepatitis C by having unprotected sex.	T	54.3 (49.1, 49.4)	Naloxone will reverse a stimulant overdose.	F	24.8 (20.3, 29.4)


Productivity software	Microsoft Office

	Endnote

	Toolbook Runtime (with modules)

Medical Software (Anatomy)	A.D.A.M

	Anatomy TV

	Grant's Atlas of Dynamic Human Anatomy

	Netter

	Imaging Modalities

	D.A.R.T.O.S.

Medical Software (Biochemistry)	Buffers

	Clustal X

	Cn3D

	Genedoc

	Graphpad Prism

	Growcyt

	Hypercell 98

	Image J

	Interactive biochemistry

	NjPlot

	Protein explorer

	Protein purification lab

	RasMol 2.6

	Spectrophotmetry

	Swiss PDB Viewer

	Trace

Medical Software (Nutrition and Dietetics)	FoodWorks

	SERV v5.5e

Medical Software (Pharmacology)	Pharma-Cal-Ogy

Medical Software (Physiology)	Acid Base

	Exercise Physiology


Number	Scenario

1	Human papilloma virus positive state

2	Cervical intraepithelial neoplasia grade I

3	Cervical intraepithelial neoplasia grade II/III

4	Cervical cancer requiring simple or radical hysterectomy

5	Cervical cancer requiring radical hysterectomy and subsequent radiotherapy (and chemotherapy)

6	Cervical cancer requiring chemoradiation therapy

7	Cervical cancer requiring chemotherapy without surgery

8	Condyloma (genital warts [condyloma acuminatum])

Number	Scenario

7	Cervical cancer requiring chemotherapy without surgery

8	Condyloma (genital warts [condyloma acuminatum])


Parameter	HMA All Lines (n = 88)	First-Line HMA (n = 41)	First-Line ICT (n = 122)	p-Value First-Line HMA vs. ICT

Median age at diagnosis, years	69	73	60	0.1698

 (min–max)	(28–88)	(44–88)	(20–86)

Male gender, n (%)	54 (61)	26 (63)	88 (72)	0.3919

BM blasts at start of treatment

 Median	22	22	24	0.8576

 Mean (Standard Deviation)	25.8 (17.2)	25.8 (15.9)	27.1 (15.8)

 Unknown, n (%)	12 (14)	2 (5)	6 (5)

Hemoglobin at start of treatment, n (%)

 ≤10 g/dL	55 (63)	32 (78)	32/64 (50)	1.00

 Pts. with unknown hemoglobin	3 (3)	0 (0)	71 (58)

Median WBC count at start of treatment, ×109/L (min–max)	2.35	2.42	1.81	0.7294

(0.1–32.3)	(0.6–24.0)	(0.2–23.9)

Neutrophil count at start of treatment, n (%)

 ≤ 0.5 × 109/L	34 (39)	18 (44)	18/57 (31)	0.7326

 Pts. with unknown neutrophil count	5 (6)	1 (2)	79 (65)

Platelet count at start of treatment, n (%)

 ≤50 × 109/L	54 (61)	24 (69)	62 (51)	0.8673

 Unknown	3 (3)	0 (0)	10 (8)

AML subtype, n (%)

 Primary	66 (75)	35 (85)	81 (66)	0.4373

 Secondary	11 (13)	4 (10)	17 (14)

 Unknown	11 (13)	2 (5)	24 (20)

MRC cytogenetic risk group, n (%)

 Good risk	1 (1)	0 (0)	0 (0)	0.6943

 Intermediate risk	39 (44)	17 (42)	51 (42)

 Poor risk	45 (51)	22 (54)	53 (43)

 Unknown	3 (3)	2 (5)	18 (15)


Molecular Category	TGFβ Sub-Family Pathway 1	BMP Sub-Family Pathway

Ligands	TGFβs, ActivinsGDF8/9/10/11, BMP3, Nodal	BMP2/4/5/6/7/8/9/10, GDF1/3/5/6/7, MIS

Type II receptors	TβRII, ActRIIA, ActRIIB	BMPRII, ActRIIA, ActRIIB

Type I receptors	ALK4, TβRI (ALK5), ALK7	ALK1/2, BMPR1A (ALK3), BMPR1B (ALK6)

R-Smad	Smad2/3	Smad1/5/8

Co-Smad	Smad4	Smad4

I-Smad	Smad7	Smad6/7

Molecular Category	TGFβ Sub-Family Pathway 1	BMP Sub-Family Pathway

Ligands	TGFβs, ActivinsGDF8/9/10/11, BMP3, Nodal	BMP2/4/5/6/7/8/9/10, GDF1/3/5/6/7, MIS

Type II receptors	TβRII, ActRIIA, ActRIIB	BMPRII, ActRIIA, ActRIIB

Type	ALK4, TβRI (ALK5), ALK7	ALK1/2, BMPR1A (ALK3), BMPR1B (AL

Molecular Category	TGFβ Sub-Family Pathway 1	BMP Sub-Family Pathway

 I receptors		K6)

R-Smad	Smad2/3	Smad1/5/8

Co-Smad	Smad4	Smad4

I-Smad	Smad7	Smad6/7


Comparison	p value	r value

Quads Strength and TWT

Baseline	0.003	-0.688

Week 6	0.003	-0.697

Week 12	0.005	-0.662

Quads Strength and TST

Baseline	0.008	-0.626

Preoperative	0.020	-0.552

Week 6	0.009	-0.618

Week 12	0.001	-0.776

Quads Strength and TCT

Preoperative	0.032	-0.508

WOMAC-Pain and TCT

Baseline	0.047	0.464

WOMAC-Function and TWT

Baseline	0.034	0.252

SF36-Physical Health and TWT

Baseline	0.009	-0.623

Week 12	0.041	-0.481

SF36-Physical Health and TST

Preoperative	0.039	-0.487

SF36-Mental Health and TCT

Week 12	0.026	-0.528


	FMF

	Rheumatic diseases (+)	Rheumatic diseases (–)

	n = 26	n = 166	p

Male/female	4/22	79/87	0.002

Age at onset (years), mean ± SD	39.3 ± 15.8	29.0 ± 16.8	0.006

Fever	24 (92.3 %)	160 (96.4 %)	0.296

Frequencies of febrile attack (per month), mean ± SD	1.01 ± 0.59	1.06 ± 0.96	0.523

Duration of fever attack (days), mean ± SD	3.0 ± 2.2	3.8 ± 4.1	0.359

Abdominal pain	3 (11.5 %)	74 (44.6 %)	0.001

Thoracic pain	4 (15.4 %)	47 (28.3 %)	0.165

Arthritis	21 (80.8 %)	87 (52.4 %)	0.007

Erysipelas-like erythema	3 (11.5 %)	31 (18.7 %)	0.281

AA amyloidosis	0	7 (4.2 %)	0.355

Family history of periodic fever	1 (3.8 %)	38 (22.9 %)	0.025


MicroRNA	Location	Model	Response	References

miR-200c	Upstream	db/db T2DM	Increase aorta endothelial dysfunction	[101]

miR-320	Upstream	High glucose treated HUVECs	Reduced expression of ET-1, VEGF, and FN	[102]

miR-133a	Upstream	STZ-induced diabetes	Prevent cardiac fibrosis	[103]

miR-1 and 6	Up stream	STZ-induced diabetes and high glucose treated NRVCs	Increase cardiomyocyte apoptosis	[104]


		Uncorrected T2Prep‐IR BOOST	Motion Corrected T2Prep‐IR BOOST

RCA	Length (cm)	7.03 ± 1.50	8.58 ± 2.27	P < 0.02

%VS (4 cm)	36.54 ± 8.63	48.31 ± 6.71	P < 0.001

%VS (tot)	37.96 ± 8.63	48.82 ± 4.63	P < 0.001


	Expression in A549

	Parental (fold)	Senescent RNA-seq (fold)	Senescent RT-PCR (fold)	Revertant RNA-seq (fold)	Revertant RT-PCR (fold)

NPTX1	1	23	40	4	6

IGF2	1	13	12	4.1	3.5

HAPLN3	1	10	38	2.8	7.4

CHAC1	1	25	22	4.2	2.7

BST2	1	207	62	10	1.5

C15orf48	1	207	9	10	2.5

NIPAL4	1	64	25	4.2	2.2

		18	98	7.	3


Cheese sample	Area assessed	a value at 144 days

Control	Top	−2.22

Side	−2.17

Base	−2.32

Center	−2.38

Exp1	Top	−2.21

Side	−2.28

Base	−2.21

Center	−1.95

Exp2	Top	−2.18

Side	−2.16

Base	−2.10

Center	−1.34b

Exp3	Top	−2.14

Side	−2.35

Base	−2.13

Center	−1.82


	Low Rate 	Medium Rate 	High Rate 	p-value

Countries with implemented screening programmes	22% (2/9)	67% (6/9)	89% (8/9)	0.014

Countries with guidelines for screening	11% (1/9)	78% (7/9)	78% (7/9)	0.005


	Reported obstetric complications or near misses

Independent variables	Eclampsia	Hemorrhage	Sepsis	Obstructed labor

	(n = 324)	(n = 4,945)	(n = 3,120)	(n = 2,847)

	Odds ratio	Odds ratio	Odds ratio	Odds ratio

Biological factors

Age 18–35 years (ref)

Age <18 years	1.35***	1.20***	1.18***	1.27***

Age >35 years	1.34***	1.27***	1.19*	1.21***

Parity 1–2 (ref)

Nulliparity	1.13**	1.10**	1.14**	1.30***

Parity >2	1.12	1.09	1.05	1.10

No previous stillbirth or miscarriage (ref)

Adverse obstetric history	1.18***	1.06**	1.12**	1.14***

MUAC ≥ 21.5 cm (ref)

MUAC < 21.5 cm	1.04	1.12*	1.16*	1.05

Socioeconomic factors

Wealth index – Lowest quartile (ref)

Wealth index - 2nd quartile	1.00	1.01	1.02	1.00

Wealth index - 3rd quartile	1.01	1.02	1.00	1.00

Wealth index - Highest quartile	1.00	1.03	1.05	1.02

Maternal illiteracy (ref)

Maternal literacy	1.01	1.01	1.04	1.03

Psychosocial factors

Both partners wanted pregnancy (ref)

Only one partner wanted pregnancy	1.02	1.06	1.08	1.07

Neither partner wanted pregnancy	1.02	1.40***	1.37***	1.28***

	Reported obstetric complications or near misses

Independent variables	Eclampsia	Hemorrhage	Sepsis	Obstructed labor

	(n = 324)	(n = 4,945)	(n = 3,120)	(n = 2,847)

	Odds ratio	Odds ratio	Odds ratio	Odds ratio

Biological factors

Age 18–35 years (ref)

	1	1.	1.18*	1

Age <18 years	.35***	20***	**	.27***

Age >35 years	1.34***	1.27***	1.19*	1.21***

Parity 1–2 (ref)

Nulliparity	1.13**	1.10**	1.14**	1.30***

Parity >2	1.12	1.09	1.05	1.10

No previous stillbirth or miscarriage (ref)

Adverse obstetric history	1.18***	1.06**	1.12**	1.14***

MUAC ≥ 21.5 cm (ref)

MUAC < 21.5 cm	1.04	1.12*	1.16*	1.05

Socioeconomic factors

Wealth index – Lowest quartile (ref)

Wealth index - 2nd quartile	1.00	1.01	1.02	1.00

Wealth index - 3rd quartile	1.01	1.02	1.00	1.00

Wealth index - Highest quartile	1.00	1.03	1.05	1.02

Maternal illiteracy (ref)

Maternal literacy	1.01	1.01	1.04	1.03

Psychosocial factors

Both partners wanted pregnancy (ref)

Only one partner wanted pregnancy	1.02	1.06	1.08	1.07

Neither partner wanted pregnancy	1.02	1.40***	1.37***	1.28***


Supernatant conditions	Protein concentration (mg/mL)	Degradation (%)

Culture supernatant	0.24 ± 0.03	50.48 ± 2.40

Super filtered culture supernatant a	1.22 ± 0.04	73.84 ± 1.65

Boiled culture supernatant	0.12 ± 0.02	52.24 ± 1.74

Supernatant conditions	Protein concentration (mg/mL)

Culture supernatant	0.24 ± 0.03

Super filtered culture supernatant a	1.22 ± 0.04

Boiled culture supernatant	0.12 ± 0.02


	Full follow-up scenario	Early mortality scenario

....Hazard ratio (95 % CI)...

cART	Yes	0 · 41 (0 · 18, 0 · 92)	0 · 28 (0 · 16, 0 · 49)

No	1 · 0	1 · 0

Cotrimoxazole	Yes	0 · 06 (0 · 01, 0 · 26)	0 · 02 (0 · 01, 0 · 07)

No	1 · 0	1 · 0

TB cure	Yes	0 · 38 (0 · 18, 0 · 84)	0 · 66 (0 · 38, 01 · 13)

No	1 · 0	1 · 0


Variables	AEP monitor group (n= 19)	RSS monitor group (n= 18)	P

Median number of propofol dosage adjustment	6 [5-7]	3 [2-3.8]	<0.001

Time to the first adjustment of the propofol dosage (second)	137 [117.5-200.5]	466 [376.5-553.5]	<0.001

Propofol dosage during examination (μg⋅kg-1⋅min-1)	43.5 [28.5-49.3]	24.2 [15.5-32.4]	0.025

Fentanyl dosage during examination (μg⋅kg-1⋅hr-1)	2.5 [1.8-3.1]	2.7 [1.9-3.4]	0.679

Percentage of propofol dosage change compared with the baseline dose (%)	93.5 [48.4-172.3]	39.5 [30.4-53.9]	0.011

Percentage of time at sedation target (%)	51.3 [47.0-63.5]	15.4 [9.5-23.5]	<0.001

Percentage of AAI levels greater than 40 during examination (%)	35.3 [27.1-51.5]	84.5 [76.5-90.4]	0.033

Patients with significant hypotension (MAP less than 60 mmHg) (%)	2 (10.5)	0 (0)	0.154

Duration of FB examination (min)	29 [27-32]	30 [28-32]	0.860

EMG (dB)	18 [16-23.5]	20 [17-25]	0.751

Variables	AEP monitor group (n= 19)

Median number of propofol dosage adjustment	6 [5-7]

Time to the first adjustment of the propofol dosage (second)	137 [117.5-200.5]

Propofol dosage during examination (μg⋅kg-1⋅min-1)	43.5 [28.5-49.3]

Fentanyl dosage during examination (μg⋅kg-1⋅hr-1)	2.5 [1.8-3.1]

Percentage of propofol dosage change compared with the baseline dose (%)	93.5 [48.4-172.3]

Percentage of time at sedation target (%)	51.3 [47.0-63.5]

Percentage of AAI levels greater than 40 during examination (%)	35.3 [27.1-51.5]

Patients with significant hypotension (MAP less than 60 mmHg) (%)	2 (10.5)

Duration of FB examination (min)	29 [27-32]

EMG (dB)	18 [16-23.5]


Total (n = 1998)	ORN/CIT	PRO/CIT	ORN/ARG	Arginine Bioavailability §

TG (	0.	0.149	0.027 *	−0


Background characteristics	Total %

Total 85 participants

Age in years

≥20	7.7

21-30 yrs	37.2

31-40 yrs	14.1

41-50 yrs	9

≤ 50	3.8

Missing data	28

Education

Illiterate	26.9

1 to 5 yrs	6.4

6 to 10 yrs	35.9

≤ 12 yrs	11.6

Missing data	19.2

Place of last birth

No child	1.3

Pregnant	3.8

Home	30.8

Govt	15.4

Private	26.9

Missing data	21.8

Number of children

No child	7.1

Pregnant	9.0

1 child	14.1

2 children	24.7

3 to 4 children	38.5

more than 4 children	4.7

missing data	1.3


	AS	FA	SS	AC	EF	WO	CLDQ

PF	0.	0.76	0.691	0.	0	0.43


CNVs	Copy numbers	Related genes	Related pathways

rs2002594; rs1986617	1	FAM162A	Mitochondrial apoptotic cascades

rs10517547; rs10517548; rs2122642; rs2345041; rs1823535; rs1823536; rs1470724	1	LPHN3	G-protein-coupled-receptor proteolysis

rs764223	1	PGAM1	Glycolysis/gluconeogenesis; metabolism of carbohydrates

rs137964; rs10483201	1	GRAP2	T cell receptor signaling pathway

rs10491333	4	HLA-DQB1	Antigen processing and presentation

rs2895201	4	SPTLC1	Sphingolipid metabolism

rs1988981; rs1321555; rs1358815; rs1964875;	4	PRIM2	Purine and pyrimidine metabolism; telomere maintenance

rs3797819; rs10515399; rs1896582; rs1366081; rs9326759	4	FER	Adherens junction

rs342597; rs10507638; rs10507639	3	DIAPH3	Regulation of actin cytoskeleton

rs10520675; rs10520671; rs7167737; rs1948066; rs10520673; rs965313	3	NTRK3	MAPK pathway

rs6816712; rs2911940; rs10517654; rs10517655; rs7662187; rs10517658	3	PDGFC	Cytokine-cytokine receptor interaction; Focal adhesion; Gap junction

rs855858; rs855860; rs10489736	3	ROR1	transmembrane receptor protein tyrosine kinase signaling pathway

rs2912	3	GAB2	Fc epsilon RI signaling pathway

rs10491050; rs7092874; rs7904118	3	SORCS1	neuropeptide signaling pathway

rs10485060; rs9322451; rs1852629	3	OPRM1	Neuroactive ligand-receptor interaction

rs1060447; rs4919231; rs1932796; rs716838; rs2169462; rs10509722	3	HPSE2	Glycosaminoglycan degradation

CNVs	Copy numbers	Related genes	Related pathways

rs2002594; rs1986617	1	FAM162A	Mitochondrial apoptotic cascades

rs10517547; rs10517548; rs2122642; rs2345041; rs1823535; rs1823536; rs1470724	1	LPHN3	G-protein-coupled-receptor proteolysis

rs764223	1	PGA	Glycolysis/gluconeogenesis

CNVs	Copy numbers	Related genes	Related pathways

		M1	; metabolism of carbohydrates

rs137964; rs10483201	1	GRAP2	T cell receptor signaling pathway

rs10491333	4	HLA-DQB1	Antigen processing and presentation

rs2895201	4	SPTLC1	Sphingolipid metabolism

rs1988981; rs1321555; rs1358815; rs1964875;	4	PRIM2	Purine and pyrimidine metabolism; telomere maintenance

rs3797819; rs10515399; rs1896582; rs1366081; rs9326759	4	FER	Adherens junction

rs342597; rs10507638; rs10507639	3	DIAPH3	Regulation of actin cytoskeleton

rs10520675; rs10520671; rs7167737; rs1948066; rs10520673; rs965313	3	NTRK3	MAPK pathway

rs6816712; rs2911940; rs10517654; rs10517655; rs7662187; rs10517658	3	PDGFC	Cytokine-cytokine receptor interaction; Focal adhesion; Gap junction

rs855858; rs855860; rs10489736	3	ROR1	transmembrane receptor protein tyrosine kinase signaling pathway

rs2912	3	GAB2	Fc epsilon RI signaling pathway

rs10491050; rs7092874; rs7904118	3	SORCS1	neuropeptide signaling pathway

rs10485060; rs9322451; rs1852629	3	OPRM1	Neuroactive ligand-receptor interaction

rs1060447; rs4919231; rs1932796; rs716838; rs2169462; rs10509722	3	HPSE2	Glycosaminoglycan degradation


Gene symbol	Description	Position (Mb)	MiRNA	Packages

RNF111	Ring Finger Protein 111	6.32–6.36	miR-142-3p	Targetscan

TCF12	transcription factor 12	6.90–7.00	miR-142-5p	MIRDB, TargetscanPicTar

ARPP19	cAMP–regulated phosphoprotein, 19 kDa	8.23–8.24	miR-142-5p	Targentscan

MYO5A	myosin VA (heavy chain 12, myoxin)	8.24–8.33	miR-142-3p	Targentscan

MAPK6	Mitogen–Activated Protein Kinase 6	8.42– 8.45	miR-142-5p	Targentscan

Gene symbol	Description	Position (Mb)	MiRNA	Packages

MAPK6	Mitogen–Activated Protein Kinase 6	8.42– 8.45	miR-142-5p	Targentscan


Variable	Number	Percentage

Intravenous drug users	20	5.8

Surgery	144	41.6

Blood transfusion	40	11.6

Transplantation	1	0.3

History of hepatitis in the family	186	53.8

Uterine curettage	12	11.9a

Dialysis	13	3.8

Dental manipulation	292	84.4

Tattoo	54	15.6

Ear Piercing	91	26.3

Circumcision	243	99.2b

High-risk sex	6	1.7

Phlebotomy	60	17.3

Variable	Number	Percentage

Surgery	144	41.6

Blood transfusion	40	11.6

Transplantation	1	0.3

History of hepatitis in the family	186	53.8

Uterine curettage	12	11.9a

Dialysis	13	3.8

Dental manipulation	292	84.4

Tattoo	54	15.6

Ear Piercing	91	26.3

Circumcision	243	99.2b

High-risk sex	6	1.7

Phlebotomy	60	17.3


Variables

Age (years)

Sex (1 = male, 2 = female)

TC (mmol/L)

Elevated WC

Elevated TG

Elevated BP

Reduced HDL-C

Smoking

HTGW

MetS


 	Perprotocol	Intention to treat

 	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value

Age

 <60 years old	1.0 (referent)	 	1.0 (referent)

 ≥60 years old	1.33 (0.61–2.92)	0.478	1.16 (0.55–2.47)	0.696

Gender

 Male	1.0 (referent)	 	1.0 (referent)

 Female	1.14 (0.53–2.46)	0.737	1.18 (0.57–2.44)	0.648

Resident area

 Urban	1.0 (referent)	 	1.0 (referent)

 Rural	1.49 (0.65–3.42)	0.342	1.12 (0.53–2.37)	0.775

Endoscopic finding

 With peptic ulcer	1.0 (referent)	 	1.0 (referent)

 Without peptic ulcer	1.05 (0.48–2.26)	0.909	1.05 (0.51–2.16)	0.900

Treatment

 CAR	1.0 (referent)	 	1.0 (referent)

 LAcR	2.67 (1.22–5.84)	0.014*	2.57 (1.24–5.33)	0.011*

	Perprotocol	Intention to treat

	Odds ratio (95%	P val		P va


 	σ (MPa)	STD	λ	STD

SV- Longitudinal	5.38	0.6	1.32	0.04

SV- Circumferential	2.61	0.67	1.55	0.06

UV- Longitudinal	1.65	0.11	1.33	0.04

UV- Circumferential	0.97	0.19	1.90	0.16


Platform	System	Applications

	IMU	GPS	LIDAR	Camera	DG payload weights	Cost	Large area	Small area	Mobility	Weather limitation	DG accuracy (3DRMS)	Cyber city	Rapid Disaster Relief

Fixed wing aircraft	Tactical grade	Geodetic grade	Yes	Digital/film	> 50 kg	High	Yes	Yes	Low	High	< 20 cm	Yes	Low

Helicopter	Tactical grade	Geodetic grade	Yes	Digital	> 50 kg	High	No	Yes	Low	High	< 20 cm	Yes	Low

UAV	MEMS	L1 phase	Yes	Digital	< 25 kg	Low	No	Yes	High	Low	< 50 cm	Yes	High

UAV Helicopter	MEMS	L1 phase	Yes	Digital	< 10 kg	Low	No	Yes	High	Low	< 50 cm	Yes	High

Platform	System	Applications

	IMU	GPS	LIDAR	Camera	DG payload weights	Cost	Large area	Small area	Mobility	Weather limitation	DG accuracy (3DRMS)	Cyber city	Rapid Disaster Relief

Fixed wing aircraft	Tactical grade	Geodetic grade	Yes	Digital/film	> 50 kg	High	Yes	Yes	Low	High	< 20 cm	Yes	Low

Helicopter	Tactical grade	Geodetic grade	Yes	Digital	> 50 kg	High	No	Yes	Low	High	< 20 cm	Yes	Low

UAV	MEMS	L1 phase	Yes	Digital	< 25 kg	Low	No	Yes	High	Low	< 50 cm	Yes	High

UAV 		L1 p	Y		< 1	Low	N	Ye			< 5	Y	Hi

Platform	System	Applications

Helicopter	MEMS	hase	es	Digital	0 kg		o	s	High	Low	0 cm	es	gh


N voxels	Gray Matter	White Matter	CSF	MD	axial	FA	FW	radial


Factors	ANC	Delivery

N = 315	N = 315

	AOR (95% CI)	P-value*	P-value**	AOR (95% CI)	P-value*	P-value**

Referral status: ref. = Referred Not referred				3.77 (1.27,11.15)	0.02	0.006


	Recipient

Male (%)	37 (74%)

Female (%)	13 (26%)

Age (yrs)	51.3 ± 11.1 (16 - 67)

BMI (kg/m2)	25.7 ± 4.73 (16.6 - 42.9)

MELD	21 ± 10.4 (6 - 40)

RRT before TPL (%)	8 (16%)

HRS before TPL (%)	17 (34%)

SAPS II	30 ± 19 (0 - 91)

Creatinine (μmol/l)	121 ± 117 (40 - 814)

Hematocrit (%)	31.4 ± 7.6 (18.8 - 49.6)

Platelets (103/μl)	106 ± 65 (33 - 324)

INR	1.5 ± 0.6 (0.9 - 4.3)

Bilirubin (μmol/l)	148 ± 198 (5 - 875)

Etiology of liver disease

HCV (%)	17 (34%)

HBV (%)	3 (6%)

HCC (%)	10 (20%)

Alcoholic liver cirrhosis (%)	6 (12%)

Cholangiocarcinoma (%)	2 (4%)

Others1 (%)	12 (24%)

Cadaveric Donor (%)

Living Donor (%)

Extended donor graft criteria (%)


 	No. of points

Risk factor	SITS SICH risk score	Extended risk score

Aspirin + clopidogrel	3	3

Aspirin monotherapy	2	2

NIHSS ≥13	2	2

NIHSS 7-12	1	1

Blood glucose ≥180 mg/dL	2	2

Age ≥72 y	1	1

Systolic blood pressure ≥146 mm Hg	1	1

Weight ≥95 kg	1	1

Onset-to-treatment time ≥180 min	1	1

History of hypertension	1	1

Total anterior circulation infarct	N/A	3

Maximal total points	12	15*

	No. of points

Risk factor	SITS SICH risk score	Extended risk score

Aspirin + clopidogrel	3	3

Aspirin monotherapy	2	2

NIHSS ≥13	2	2

NIHSS 7-12	1	1

Blood glucose ≥180 mg/dL	2	2

Age ≥72 y	1	1

Systolic	1

	No. of points

Risk factor	SITS SICH risk score	Extended risk score

 blood pressure ≥146 mm Hg		1

Weight ≥95 kg	1	1

Onset-to-treatment time ≥180 min	1	1

History of hypertension	1	1

Total anterior circulation infarct	N/A	3

Maximal total points	12	15*


Variable	Level of knowledge

Adequate

Age

15–24	53 (57%)

25–35	115 (64.2%)

36–45	31 (54.4%)

>45	9 (22%)

Marital status

Married	190 (59.6%)

Single	6 (31.6%)

Widowed	2 (20%)

Divorced	10 (45.5%)

Educational status

Illiterate	87 (40.1%)

Primary (1–8)	32 (57.1%)

Secondary and above	89 (91.6%)

Occupational status

Housewife	123 (50.8%)

Government emp∗	61 (98.4%)

Private employee	5 (41.7%)

Daily laborer	10 (28.6%)

Merchant	9 (64.3%)

Farmer	2 (40%)

Number of children

1-2	149 (63.1%)

3-4	55 (46.6%)

>4	4 (25%)

Information about diarrhea

No information	6 (12.8%)

Have information	202 (62.5%)